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There is ample evidence of disturbed membrane phospholipid metabolism and oxidative stress 
in schizophrenia. Trials with fatty acid and antioxidant supplementation have shown 
conflicting results as regards symptoms. This study is part of a larger multicenter, double-
blind, placebo-controlled trial of Ethyl-Eicosapentaenoic Acid (EPA) and antioxidants 
(vitamins E and C) as add-on to antipsychotic drugs in younger patients with schizophrenia 
and related disorders.  
 
In the present study, we tested the effect of trial drugs on cognitive functioning in a 
geographically defined subgroup of these patients. Both patients (n=53) and controls (n=20) 
completed a broad battery of neuropsychological tests and were tested at baseline and at week 
16. PUFA levels were measured in red blood cell (RBC) membranes. The longitudinal effects 
were analysed by Linear Mixed Model (SPSS 12.0). We expected the following hierarchy of 
effects, from greater to lower: 1) combined EPA and antioxidant treatment, 2) EPA or active 
antioxidants alone and 3) double placebo. 
 
In contrast to our expectations, performance on CPT and Stroop was impaired in the groups 
receiving single supplements. Antioxidants prolonged the Stroop- conflict time and EPA 
impaired sustained attention, as measured by CPT dprime. These effects were restricted to the 
low-PUFA group, according to the bimodal distribution of PUFA levels found in the larger 
study. Combining EPA and antioxidants had a non-significant beneficial effect on sustained 
attention in the low-PUFA group only, compared to placebo. There were no other significant 
effects of trial drugs on neuropsychological measures. 
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1.0 Introduction  
Worldwide, schizophrenia affects 1% of the population and describes a heterogenic 
group with a variety in symptoms, prognosis and functioning (Austin, 2005). 
Schizophrenia is often chronic and affects people at a young age. The illness is also 
associated with low premorbid functioning and social difficulties. About three quarters 
of patients with schizophrenia suffer recurrent relapse and continued disability 
(Nadeem, McIntosh and Lawrie, 2004) and need treatment for the rest of their lives. 
Onset of first time psychosis in schizophrenia occurs typically in late adolescence or 
early adulthood (Mueser and Salyers, 2003; Perkins, Lieberman and Lewis, 2006). Time 
of onset is associated with course and outcome, where later onset of first time psychosis 
predicts less relapse and better prognosis (Mueser and Salyers, 2003). Prognosis is also 
influenced by other factors, such as; gender, marriage and social function (Perkins, 
Miller-Andersen and Lieberman, 2006). On average, women often spend less time in 
hospitals, have less severe psychopathology and show better social competence than 
men (Malt, Retterstøl and Dahl, 2003; Perkins et al., 2006). The clinical picture of 
schizophrenia contains “positive” and “negative” symptoms (Lindenmayer and Khan, 
2006). Symptoms of “positive” nature are those of active, hallucinating and delusional 
type, whereas the “negative” symptoms describe the more passive traits, as blunted 
affect, lack of motivation, and self neglect (e.g. Austin, 2005; Lindenmayer and Khan, 
2006). The last decades research on this clinical group have raised questions about the 
validity of the schizophrenia diagnose. The heterogeneity of this disorder laid ground 
for the assumption that there exist diverse subtypes in this group. It is likely that 
schizophrenia as currently defined involve several heterogeneous disease processes 
(Sullivan, Owen, O`Donovan and Freedman, 2006). The fact that subgroups have 
different course and prognosis creates the basis for classification systems (Malt et al., 
2003).  
 
Cognitive deficits are often reported as a core feature in individuals with schizophrenia 
and are seen to account for much of the impairment in their functioning (Green, 2006). 
People with schizophrenia often experience a cognitive decline associated with illness 
onset, but the level of cognitive functioning tends to remain relatively stable over time 
(Mueser and McGurk, 2004). The cognitive impairments in schizophrenia are often 
divided in three domains; verbal learning/memory, attention and executive functions. 
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Improving cognition is an important target for treatment because it has profound effect 
on psychosocial function. 
 
Historically, patients with schizophrenia have been a stigmatized group, with little hope 
for sustained remission and recovery of functioning. Countering this perspective, new 
findings suggest that the illness can be favourably influenced by comprehensive and 
continuous treatment (Liberman, Kopelowicz, Ventura and Gutkind, 2002). Research on 
prognosis has also implemented the heterogeneity of schizophrenia when focusing on 
good prognostic variables in subgroups of patients achieving full remission or a 
continually symptom-free condition (Torgalsbøen, 2005). This good prognosis group is 
characterized by a later debut, an acute onset with positive symptomatology, have a 
higher share of women and do not display the typical cognitive deficits and enlarged 
ventricles associated with a more chronic prognosis (Torgalsbøen, 2005; Keefe and 
Eesley, 2006). 
 
Treatment of schizophrenia is currently based on administration of antipsychotic 
medications that reduces the most prevailing symptoms of schizophrenia, like anxiety, 
hallucinations, delusions and rage, but leaves the negative symptoms and cognitive 
deficits unchanged (Mahadik and Yao, 2006). Whereas 50%-68% of treated patients 
have long term favourable outcome, many obtain less than optimal results from current 
medications (Mahadik and Yao, 2006). Taken together with the array of morbidities 
following such medication, such as weight gain, lethargy, insulin resistance, 
cardiovascular problems and abnormal lipid metabolism, it leads to a decline in the 
patient’s quality of life and poorer lifetime prognosis (Austin, 2005; Mahadik and Yao, 
2006). This underpins the importance of looking into new aspects of treatment, like in 
this study, where the therapeutic effect of fatty acids and antioxidants on cognition is 
investigated.  
 
1.1. The aetiology of schizophrenia 
The aetiology of schizophrenia is complex and has a multifactorial origin. A number of 
explanations that range from genetic models to those that attribute the disease to social 
environment are set out. The aetiology is still not fully understood, but it seems 
reasonable to divide the contributing aetiological factors in three groups; biological, 
psychological and social (Malt et al., 2003).  
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Data of twin and adoption studies highlight the importance of both genetic and 
environmental factors in the development of the illness (Austin, 2005).  The genetic 
relatedness to an affected family member has shown to correlate with the risk of 
developing schizophrenia (Hollis, 2005; Sullivan et al., 2006) and it has an estimated 
heritability of 60%-85% (Merikangas and Risch, 2003). Efforts to identify genes 
involved in schizophrenia are emerging, and evidence support some candidate genes, 
but no chromosomal loci or genes have been unequivocally demonstrated (Mueser and 
Salyers, 2003; Sullivan et al., 2006). Aetiological research also strives to discern 
biological markers in the pathogenesis of schizophrenia. Much focus has been directed 
at endophenotypes1 that are intermediate between genetic predisposition and the clinical 
phenotype, but no markers of sufficient sensitivity and specificity have been found 
(Lewis, 2004; Sullivan et al., 2006).  
 
Considerable evidence also supports the importance of environmental factors like 
abnormal fetal milieu and complications during pregnancy and/or delivery (Mahadik, 
Pillai, Joshi and Foster, 2006). Risk factors contributing to this are: prenantal and 
neonatal infections, famines, maternal malnutrition, alcohol and drug abuse, season of 
birth and acute life events (Nadeem et al., 2004; Mahadik et al., 2006). The precise 
contributions of these factors and the how they interact are not clear (Nadeem et al., 
2004). A critical and emotionally over involved family atmosphere has also been 
implicated as a contributing factor in the development of schizophrenia (Breitborde, 
Lopez, Wickens, and Karno, 2007). This is conceptualized as “expressed emotion” (EE) 
in the literature. Parental hostility is found to predict relapse and to influence onset 
(Breitborde et al., 2007). Furthermore, sosiodemographic factors are also suggested to 
have a causal role as schizophrenia is overrepresented in lower social classes. The “drift 
hypothesis” and the “social causation hypothesis” are two theories that are set out to 
explain this occurrence (Kringlen, 2001). The drift hypotheses propose that suffering 
from a major mental illness like schizophrenia affects occupational functioning and 
make them drift downward in social class. The social causation hypotheses propose that 
experiencing the type of stress that poverty brings; elicit the predisposition of 
schizophrenia more frequently (Kringlen, 2001). 
                                                 
1 An endophenotype is an intermediate expression of the genetic expression of the genetic predisposition for a 
disease that is expressed endogenously, in difference to exogenous/observable, like behaviour (Lewis, 2004). 
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The leading model of schizophrenia during the past century has been the Kraepelinian 
notion of degenerative disease, conceptualised in the term dementia praecox (Keshavan, 
Gilbert and Diwadkar, 2006). During the past few decades research in neuropathology 
has made an extensive contribution to the understanding of cellular and molecular 
mechanisms of schizophrenia. In line with this, the view of schizophrenia as a 
“functional” psychosis has changed to the current paradigm of schizophrenia as a 
neurodevelopment disorder (Chaturvedi and Thakur, 2003). The view that abnormal 
neurodevelopement may underlie schizophrenia has been gaining acceptance in recent 
years. Observations of pre-morbid behavioural, neurocognitive, and minor physical 
anomalies together with evidence of risk factors to brain adversity before the clinical 
manifestation of the illness is regarded as the strongest, although indirect, evidence of 
disordered neurodevelopement in schizophrenia (Keshavan et al., 2006). Over the past 
two decades, at least three developmental formulations have been suggested (Hollis, 
2005). One formulation postulate altered pre-or perinatal brain development, another 
suggests peri-adolcent development abnormalities and thirdly, there are theories arguing 
for progressive neuroregressive processes after illness onset (Keshavan et al., 2006). 
There are evidence supporting all three perspectives, and preliminary evidence also 
suggests that they are not mutually exclusive (Keshavan et al., 2006).  
 
It has been increasingly support around the term “schizo-spectrum” disorders as a 
dimensional perspective on schizophrenia. This is also being referred to as “schizotaxia” 
in the literature, to describe the unexpressed genetic liability to schizophrenia (Hollis, 
2005; Lewis, 2004). This dimensional theoretical approach can be understood in the 
light of the “diathesis-stress model”, where the amount of stress an individual 
experiences awakens the inherited diathesis to a smaller or greater extent. In this view, 
an individual with the same diathesis, but with different environmental experience can 
e.g. stay healthy; develop a schizotypal personality disorder or schizophrenia. The 
definitional boundaries of this spectrum however, are uncertain (Sullivan et al., 2006).  
 
To summarise, schizophrenia is a heterogeneous disorder as for aetiology, pathogenesis 
and phenotype. Today it is common to view the disorder in a neurodevelopmental 
perspective and to conceptualise schizophrenia in the framework of the diathesis-stress 
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model. One main challenge in this field is to specify validated subgroups, first as regard 
to phenotypes, then as regards to pathogenesis and aetiology (Compton, 2004). 
 
1.2 The patophysiology of schizophrenia  
Schizophrenia is associated with a broad range of neurodevelopmental, structural and 
behavioural abnormalities that often progress with or without treatment (Mahadik et al., 
2006). Neuropathology can be defined as a consistent cellular abnormality found in the 
nervous system (Halliday, 2001).The main positive neuropathological findings in 
schizophrenia concern neuronal morphology, organisation and presynaptic and dendritic 
parameters (Harrison, 2004). The leading neurochemical hypothesis of schizophrenia 
has concerned the dopamine pathways, especially since current medications for 
schizophrenia work primarily through the blockade of the D2-receptor (Javitt and 
Laurelle, 2006). Schizophrenia is also associated with other biochemical abnormalities 
involving serotonin, glutamate, and gamma -aminobutyric acidergic systems (Malt et 
al., 2003; Javitt and Laurelle, 2006). The relationship between any neurochemical and 
structural abnormality remains unclear. 
 
With advances in imaging techniques, there are now consistent reports of structural and 
functional differences in the brains of people with schizophrenia in comparison to 
controls (Halliday, 2001; Harrison, 2004). These include ventricular enlargement and 
decreased cortical- and hippocampal volume (Halliday, 2001). Several studies have also 
yielded decreased frontal lobe volumes in grey and white matter (Belger and Dichter, 
2006). Volume decreases are found to have functional consequences, where for instance 
frontal lobe grey matter has been linked to severity of negative symptoms (Belger and 
Dichter, 2006). There is also observed expanded or reduced sulci, giving support to an 
aberrant brain development not only in the subcortical areas, but in cortex as well 
(Lingjærde, 2002). In addition, the frontal and temporal lobes and their thalamic relays 
also appear to be particularly affected in schizophrenia (Halliday, 2001). Some 
researchers suggest that the pathophysiology of schizophrenia reflects unusual/abnormal 
activity and integration of the components of distributed circuits in the brain. These 
circuits involve the prefrontal cortex, hippocampus and certain subcortical structures 
(Harrison, 2004). This points out that there seems to be “global changes” in brain-
systems or circuits, rather than alterations in only one area of the brain (Malt et al., 
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2003; Belger and Dichter, 2006). However, as mentioned above, the neuropathology of 
schizophrenia and how the pathology is expressed as phenotypes is still uncertain. 
 
2.0 The cell membrane (phospholipid) hypothesis and oxidative stress 
It has been known for a long time that diet have profound effect on physical and mental 
health; for example are certain dietary risk factors for physical health also risk factors 
for depression and cognitive impairment (Peet, 2001). Here, we primarily focus on the 
mechanisms of fatty acids and antioxidants. Polyunsaturated fatty acids (abbreviated as 
PUFA`s) and antioxidants are required for the maintenance of optimal health, but are 
only partly synthesized in the body and need supplies from dietary sources. Patients 
with schizophrenia often consume a poor diet due to the nature of negative symptoms 
which affects their ability to take care of their health. Recognition of the importance of 
nutrition for mental health together with hypotheses on altered cell metabolism (the 
phospholipid hypothesis) and impaired antioxidant defence system (AODS) in patients 
with schizophrenia, have generated a body of research on the therapeutic effect of 
antioxidants and fatty acids.  
 
Observations of altered membrane phospholipid composition in people with 
schizophrenia have been reported for decades (Du Bois, Chao and Huang, 2005). These 
changes have been considered to be a result of a distorted metabolism (reduced 
synthesis and/or increased breakdown) of fatty acids. The membrane is consist of a 
collection of phospholipids (complex molecules containing phosphorus and essential 
fatty acids) as well as receptors and a number of other structures that are responsible for 
the cell-metabolism (for an illustration, see figure 1 in Appendix, 10.1). Theories about 
the neuronal membrane describes how essential fatty acids, such as arachiodonic acid 
(AA) from the omega-6 family, and  docosahexaenoic acid (DHA) from the omega-3 
family, play important roles in neurotransmission once they are incorporated into the 
membrane (Fenton, Hibbeln and Knable, 2000). Phospholipid composition of PUFA`s 
is a premise for the dynamic state of all membranes, especially neuronal (Mahadik and 
Yao, 2006). The cell membrane hypothesis, also referred to as the phospholipid 
hypothesis, proposes that the neuropathology of schizophrenia is mediated by, or has its 
offspring in a dysfunctional neuronal metabolism. Horrobin (1977) was the first 
researcher proposing a link between schizophrenia and a dysfunctional cell membrane, 
more specifically a deficiency in chemicals called prostaglandins that are manufactured 
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from essential fatty acids. PUFA influence many important intracellular processes, like 
the activity of ion-channels, enzyme activity, transporters and receptors. A change in 
membrane phospholipid composition may therefore affect neurotransmission. In turn; 
these modifications can affect cognition and behaviour through multifaceted 
downstream biological effects (Fendri, Mechri, Khiari, Othman, Kerkeni and Gaha, 
2006). 
 
Several mechanisms causing the membrane pathology in schizophrenia has been 
proposed; 1) reduced levels of polyunsaturated fatty acids, 2) increased activity in 
phospoliphase A2 and 3) oxidative stress (Skrede and Holmsen, 2003).  
 
Lack of polyunsaturated fatty acids are consistently reported in red blood cells 
(RBC`s)2, brain and skin fibroblasts in chronic-medicated schizophrenic patients as well 
as never medicated patients (Assies, Lieverse, Peter, Wanders, Dingemans and 
Linsezen, 2001). Reduced levels of membrane PUFA is associated with other 
neuropsychiatric conditions including Attention Deficit (Hyperactivity) Disorder, 
Alzheimers`s Disease, Depression and psychopathology in general (Young and 
Conquer, 2005; McNamera, and Carlson, 2006). Similarly, the level of RBC PUFA`s 
has been found to inversely correlate with the severity of psychopathology, where 
increased PUFA`s correlate with reduced psychopathology (Mahadik, Evans and Lal, 
2001).  
 
Increased activity in the enzyme pospholiphase A2 (PLA2), an enzyme breaking down 
phospholipids by splitting polyunsaturated fatty acids, have also been reported among 
patients with schizophrenia (Ross, Hudson, Erlich, Warsh and Kish, 1997). This activity 
can have two broad effects on the cell membrane: direct physical-chemical changes that 
influence proteins and enzymes, or through an imbalance in cell communication (Skrede 
and Holmsen, 2003). The low levels of PUFA`s combined with increased activity of the 
enzyme phospholiphase A2 may be causally linked to the membrane pathology in 
schizophrenia. For example might increased levels of phospholiphase A2 reflect a 
                                                 
2 Red blood cell (RBC) levels of PUFA are considered a reliable measure in reflecting the percent of total fatty 
acid, and the distribution of these in the CNS (Khan, Evans, Gunna, Scheffer, Parikh and Mahadik, 2002). 
. 
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compensatory mechanism removing perioxidative PUFA`s from the neuronal membrane 
(Skrede and Holmsen, 2003).  
 
Another mechanism associated with this psychopathology in schizophrenia is the 
process of oxidative stress. Oxidative stress is defined as a state where there is 
unbalance between the generation of free radicals and the antioxidant defence system 
(AODS) (Fendri et al., 2006). Free radicals are a consequence of the cells interaction 
with oxygen as part of the energy producing process of the body. They are short-lived 
and are usually inactivated by antioxidants before they can damage genes, proteins or 
PUFA`s (Mahadik and Yao, 2006). The AODS blocks the initiation of free radical chain 
reactions (Mahadik and Mukherjee, 1996). Both the antioxidant enzymes, already 
existing in the body, and antioxidants obtained from diet (non-enzyme antioxidants), are 
very important in the overall AODS. The non-enzymatic antioxidants (like vitamin E 
and C) inactivate free radicals by scavenging (Mahadik and Yao, 2006). The detection 
of abnormal antioxidant enzyme activity (Fendri et al., 2006), and lowered levels of 
plasma antioxidant proteins (Yao, Reddy and Kammen, 2001) supports a deficient 
antioxidant system (AODS) in schizophrenia, secondary to a free radical-medicated 
pathology caused by oxidative stress.  
 
In sum, there is evidence of reduced levels of PUFA`s, increased lipid peroxidation and 
an impaired antioxidant defence system (AODS) in patients with schizophrenia. This is 
consistent with high levels of oxidative stress. Antioxidant defence systems exists to 
protect against oxidative stress, but in schizophrenia there is evidence for a 
dysregulation of free radical metabolism (Reddy and Yao, 1996). It is suggested that the 
ongoing oxidative injuries can be prevented by dietary supplementation of antioxidants 
(e.g., vitamins E, C and A; flavons, beta-carotene, Q-enzyme etc.) and that the depleted 
membrane phospholipids can be adjusted by dietary supplementation of PUFA`s 
(Mahadik and Mukherjee, 1996). Preliminary evidence of improved outcome of patients 
with schizophrenia given PUFA`s and antioxidants indicates favourable effects of such 
dietary supplementation (Mahadik and Mukherjee, 1996). The flow diagram (figure 1) 
shows how the impaired antioxidant defence system (AODS) of oxidative stress may 
lead to membrane phospholipid peroxidative breakdown and the pathophysiological 
consequences that may contribute to development of schizophrenia symptomatology.  
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Figure 1 
 
Source: Adapted from Yao et al. (2001). 
 
2.1 Literature review 
 
2.1.2 Fatty acid 
Evidence in support of PUFA-deficiency as a risk factor for schizophrenia is provided 
by four primary areas of research: 1) cross-national epidemiological studies demonstrate 
improved course and outcome of schizophrenia in populations whose average national 
diets contains high levels of  unsaturated fat compared to levels of saturated fat and total 
fat consumption (Christensen and Christensen, 1988), 2) reduced fatty acid (plasma and 
red blood cells) concentrations in patients with schizophrenia (Reddy, Keshavan and 
Yao, 2004), and other neuropsychiatric conditions (Young and Conquer, 2005), 3) 
randomized, double-blind, placebo-controlled clinical trials and case studies showing 
that dietary intake of EPA reduces symptom severity (Laugharne, Mellor and Peet 1996; 
Emsley, Myburgh, Oosthuizen and van Rensburg, 2002), and 4) studies presenting the 
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positive effects of  DHA-intake on mental development of children (Werkman and 
Carlson, 1996; Lauritzen, Jorgensen, Hansen and Michalsen, 2002; Helland, Smith, 
Saarem, Saugstad and Drevon, 2003).  
 
The association between cognitive functioning and fatty acids has not been 
comprehensively explored. One study by Fontani, Corradeschi, Felici, Alfatti, 
Migliorini and Lodi (2005) investigated the effect of omega-3 supplementation on some 
cognitive and physiological parameters in healthy subjects. The results showed that the 
mood-profile improved (e.g. reduced anger and anxiety states and increased vigour), 
and this was further associated with an effect on reactivity with a reduction of reaction 
time in the Go/No-Go and Sustained attention tests. The researchers concluded that 
omega-3 supplementation is associated with an improvement of attentional and 
physiological functions, particularly those involving complex cortical processing in 
healthy subjects. However, this study was not randomized and placebo controlled, and 
concerned healthy subjects.  
 
Few researchers have investigated the effect of fatty acids and/or antioxidants on 
cognitive functions in schizophrenia. We searched for these kinds of studies in EBSCO, 
Pubmed, Psychinfo and Medline databases and were only able to find one article on this 
topic, executed by Fenton, Dickerson, Boronow, Hibbeln and Knable (2001). This is 
surprising, since cognitive functions are considered to be a fundamental deficit in 
schizophrenia.  
 
The article by Fenton et al. (2001), investigated 87 patients with schizophrenia in a 16-
week, double blind supplementation trial. The intervention group receiving 3 grams of 
EPA per day did not improve their cognitive performance compared to the group treated 
with placebo. This paper only explored the effect of fatty acid and only included traces 
(not active dose) of antioxidants-supplement. Fenton et al. (2001) suggest that dietary 
supplementation among less severely ill patients earlier in their illnesses and/or that a 
different EPA dose or treatment duration should be considered in further studies.  
 
In order to explore the phospholipid hypothesis in schizophrenia Peet, Laugharne, 
Mellor and Ramchand, (1996) measured PUFA levels in patients. They found 
depletions in fatty acids, with the most significant reduction reported for AA and DHA. 
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This adds to the evidence on reduced PUFA levels in people with schizophrenia. 
Another study by Laugharne et al., (1996) gave subjects with a schizophrenia diagnoses 
ten grams of EPA per day, and found a significant decrease in scores on the Positive and 
Negative Syndrome Scales (PANSS) after six weeks. Moreover, the PUFA levels in 
patients’ blood correlated directly with the improvement of their symptoms (Laugharne 
et al., 1996). A measure of tardive dyskinesia, a side effect of many anti-psychotic 
drugs, did also improve significantly with the EPA supplementation in this study.  
 
More recently, a randomized, double-blind, placebo-controlled study by Emsley et al., 
(2002) investigated the effect of giving either three grams of EPA per day or placebo in 
addition to their usual anti-psychotic medications. The patients taking EPA showed a 
significant reduction of negative and positive symptoms of schizophrenia, as well as 
symptoms of tardive dyskinesia. Despite positive results like this, reviews going 
through published trials investigating PUFA`s effect on schizophrenia are mixed. While 
some studies have found an effect of EPA on tardive dyskinesia and PANSS (Emsley, et 
al., 2002), others have failed to replicate this findings (Emsley, Niehaus, Koen, 
Oosthuizen, Turner, Carey, van Rensburg, Maritz and Murck, 2006). These equivocal 
results may be explained by a variety of variables like dose, age, duration of use, type of 
fatty acid and the heterogeneity of the schizophrenia population. 
 
2.1.3 Antioxidants 
Several studies have tried to disentangle the effects of antioxidants, fruit and vegetable 
consumption on cognitive functions. Studies show that both vitamin-E (Morris, Evans, 
Dienias, Tangney and Wilson, 2002), vegetable consumption (Morris, Evans, Tangney, 
Bienias and Wilson, 2006) and adjunctive use of E or C vitamin and/or multivitamin 
(Maxwell, Hicks, Hogan, Basran and Ebly, 2005) is associated with reduced risk for 
cognitive decline in elderly populations. One cross-sectional, naturalistic study 
investigated antioxidant use (vitamin E and C) in community-dwelling elderly women 
(Grodstein, Chen and Willett, 2003). This study showed that long-term, current users of 
vitamin E and C had better mean performance on cognitive tests, compared to women 
who had never used vitamin E or C (Grodstein et. al., 2003). The researches also found 
a tendency for higher mean scores with increasing duration of use. The benefits were 
also greater for women taking vitamin E and C in combination (Grodstein et al., 2003). 
Hovewer, Kang, Cook, Manson, Buring, and Grodstein (2006), did not find that long-
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term use of vitamin E supplements gave cognitive benefits among healthy female 
subjects. In addition, a randomized double-blind placebo-controlled study of antioxidant 
vitamin supplementation in the elderly yielded no significant effect of supplementation 
on mood or cognitive function (Smith, Clark, Nutt, Hayward and Perry 1999; Smith, 
Clark, Nutt, Hayward and Perry, 2000).  
 
In treatment of schizophrenia, vitamin E supplementation has proved to improve 
symptoms of tardive dyskinesia (TD) (Mahadik and Gowda, 1996). In a total of 14 
studies, all but two (Adler, Rotrosen, Edson, Lavori, Lohr, Hitzemann and et al., 1999; 
Shriqui, Bradjewejn, Annable and Jones, 1992) found vitamin E beneficial in 
controlling some symptoms of TD and psychopathology (Mahadik et al., 2006).  
The effect of vitamin C in patients with schizophrenia is less explored, as we found only 
one study carried out by Dakhale, Khanzone, Khanzone, and Saoji (2005). This is the 
first study to investigate a single supplementation of vitamin C on forty patients with 
schizophrenia. Their prospective, double-blind and placebo-controlled study, revealed 
that vitamin C supplementation added on the patients typical antipsychotic medication 
reduced measures on oxidative stress, reversed the initially low levels of ascorbic acids 
(vitamin C) and improved scores on the Brief psychiatric rating scales (BPRS) score 
compared to placebo with atypical antipsycotics (Dakhale et al., 2005). 
 
In summary, fatty acids have yielded mixed results in treatment of symptoms in 
schizophrenia. In a review of all randomized trials of fatty acids in the treatment of 
schizophrenia, Joy, Mumby-Croft and Joy (2006) conclude that the supplement of fatty 
acids reduces the need for antipsychotic medication and may improve their mental state, 
but that the use of fatty acids in schizophrenia is still experimental. The researches 
highlight the need for large well designed studies to ensure the effect of fatty acids in 
schizophrenia (Joy et al., 2006). In regard to antioxidants like vitamin E and C, 
epidemiological studies have not been able to establish a consistent relationship 
between antioxidant status and cognitive functioning in generally healthy subjects. 
However in schizophrenia, both antioxidants have shown to reduce psychopathology 
and symptoms of TD. Finally, the effects of fatty acids or antioxidants on cognitive 
functioning in schizophrenia are minimally explored. Our conclusion is that there is a 
shortage of research studying the association between cognition and dietary 
supplementation of fatty acids and antioxidants in individuals with schizophrenia 
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2.1.4 Interaction-effects 
The only study using a combination of fatty acids and antioxidants in people with 
schizophrenia was done by Arvindakshan, Ghate, Ranjekar, Evans and Mahadik (2003). 
Arvindakshan et al., (2003) investigated the outcome on symptom-scales when patients 
with schizophrenia were given a combination of fatty acids and antioxidants (vitamin E 
and C). They found a significant reduction in psychopathology based on reduction in 
individual total BPRS, PANSS and general psychopathology -PANSS. Additionally, 
they found an increase in Henrich`s Quality of Life (QOL) scale. Unfortunately, Fenton 
et al., (2001), only used traces of antioxidants in his study so we did not find any 
demonstrations of the interaction effect of antioxidants and fatty acids on cognition in 
individuals with schizophrenia. 
 
In sum, no consistent pattern linking fatty acids and antioxidants to better cognitive 
outcome in schizophrenia has been identified (Addington, 2000). Studies investigating 
fatty acids in relation to deficits of the cell membrane and psychiatric disorders have 
pointed to several critical issues in designing and carrying out new studies (Mahadik 
and Evans, 1997, Fenton et al., 2000; Mahadik et al., 2001). One important aspect 
concerns the age of patients used as participants. This is essential because after 45 years 
of age the antioxidant defence declines rapidly, and adjunctive use of antioxidants may 
be critical. Secondly, duration of illness is also vital because some typical antipsychotics 
have been found to have a pro-oxidant property (Jeding, Evans, Akanmu, Dexter, 
Spencer and Aruoma et al., 1995). Thus, long-term use of typical antipsychotics may 
have entailed membrane pathology that may be difficult to correct. Other important 
factors are the type and dose of PUFA`s given to the subjects. Thus, the combined use 
of the antioxidants and PUFA`s may be necessary for optimal treatment of oxidative 
cell injury. Few studies reported so far involve the use of both supplements in patients 
with schizophrenia.  
 
3.0 Schizophrenia and cognition 
The pattern of cognitive deficits found in schizophrenic patients is widely accepted as a 
characteristic of schizophrenia (Lewis, 2004), yet it has never been included in any of 
the major diagnostic criteria systems. It is an ongoing debate whether the diagnostic 
criteria for schizophrenia should be reconsidered (Tsuang and Faraone, 2002; Lewis, 
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2004). It is argued that diagnostically it is an overreliance on psychotic symptoms, 
which are not specific to the schizophrenia diagnose. Some researchers even postulate 
schizophrenia to be a cognitive disorder (Green, Nuechterlein and Gold, 2004). Lewis 
(2004) proposes that cognitive deficits should be included for clinical and educational 
reasons, and as a way to identify vulnerable pre-psychotic children and adolescents. The 
cognitive deficits are well established by research, where families with an affected 
member are found to have the same pattern of abnormal cognitive functioning when 
tested neuropsychologically (Hollis, 2005). This rules out the perspective where 
cognitive deficits in schizophrenia is secondary to psychotic symptoms. Severely 
impaired performance on cognitive tests is the strongest evidence for the importance of 
cognitive deficits in schizophrenia. Stable cognitive functions might also be favourable 
to prevent relapse, or increase time between relapses. This is also why many specialised 
cognitive training-programs are under development (Ueland, 2005). 
 
Cognitive impairments found in individuals with schizophrenia includes problems in 
speed of processing, attention/vigilance, working memory, verbal learning, visual 
learning, reasoning and problem solving, and social cognition (Keefe and Eesley, 2006). 
Green (2006) also suggests that these deficits can serve as an endophenotype for the 
illness in studies of genetics. Analyses of data from 150 patients with schizophrenia 
suggest that up to 98% of patients perform worse on cognitive tests than would be 
predicted by their parents education level (Keefe, Eesley and Poe, 2005).Consistent 
findings report a lowered IQ-score in individuals with schizophrenia (Keefe and Eesley, 
2006). The average impairments can reach 2 standard deviations below the healthy 
control mean in several cognitive domains (Keefe and Eesley, 2006).  
 
According to Bowie and Harvey (2006) deficits across neurocognitive domains such as 
attention, working memory, language skills, and executive functions tend to be 
moderate, with the most pronounced deficits found in verbal learning and memory. In 
general, the domains that are most consistently cited as being severely impaired in 
schizophrenia are in memory, attention/vigilance and executive functions (Malt et al., 
2003). Next we will elaborate on these domains. 
 
3.2 Verbal learning and memory 
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Patients with schizophrenia demonstrate memory deficits in a variety of different tasks. 
Deficits include problems with working memory, episodic and semantic memory, while 
implicit memory remains intact (Egeland, Sundet, Rund, Asbjørnsen, Hugdahl and 
Landrø et al., 2003).  Knowledge of deficits in semantic memory is important because it 
is closely related to thought disturbances, which are regarded as a core symptom of 
schizophrenia. Memory can be divided into three parts; encoding, retention and 
retrieval. In terms of episodic memory, evidence indicates that encoding is the most 
vulnerable part of the memory process for patients with schizophrenia (Egeland et al, 
2003).  It is also clear that these deficits are not secondary to nevroleptic medication, 
attentional struggles or differences in subgroups (Egeland and Landrø, 2005). Research 
indicates that this finding does not reflect the general lowering in IQ amongst patients 
with schizophrenia (Egeland and Landrø, 2005). 
 
The abilities involved in memory functioning include those associated with learning 
new information, retaining newly learned information over time and recognizing 
previously presented material (Keefe and Eesley, 2006). In general, patients show larger 
deficits in learning than in retention (Keefe and Eesley, 2006). The findings for 
recognition are vaguer, where relatively mild and large deficits have been reported. The 
tests used to measure learning typically involve the ability to learn lists of words or 
written passages. After five repeated trials of the same word list, most control subject 
can recall at least 13 of the words (total of 16), while patients with schizophrenia on 
average solely recall 9 (Keefe and Eesley, 2006). Additionally, patients with 
schizophrenia can recall about 5 words after the first trial, while healthy controls recall 
approximately 8 words. Hence, patients are impaired both in their ability to learn over 
time and in immediate recall compared to control subjects.   
 
3.3 Attention 
Many neurocognitive tests require vigilance functions, even if the test itself is not a 
measure of “pure” vigilance. Vigilance refers to the ability to maintain attention over 
time. The Continious performance test (CPT) is a standard vigilance test used in several 
studies. Attentional vigiliance and a reduced capacity to focus are considered both as a 
core symptom and as an underlying mechanism for other cognitive dysfunctions (Borg 
and Rund, 1999). Studies show that people with schizophrenia perform poorer than 
healthy controls on task of attention (Chen, Chang, Liu, Hwang and Hwu, 2004). 
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Deficits in sustained attention remain relatively unchanged through symptom 
fluctations, illness stages, and were not changeable with neuroleptics when more 
difficult CPT versions were used (Liu, Hwu and Chen, 1997 and Hong, Kim, Koh, Koo, 
Kim and Lee et al., 2002). Span of Apprehension-tests (SPAN), Backward Masking test 
and different versions of the CPT are common assessments used to investigate 
performance in attention.  
 
Attentional impairments are also seen in pre-psycotic people before they exhibit signs of 
schizophrenia (Chen et al., 2004). It has also been explored if non-psychotic relatives of 
schizophrenic and schizotypal probands have an elevated risk of deficits in sustained 
attention as measured by CPT. In their study Chen et al. (2004) concludes that relatives 
of both schizophrenic and shizotypal personality disorder show poorer performance in 
comparison to controls, but that the effect was more profound for the schizophrenic 
relatives than for the shizotypal probands (Chen, Liu, Chang, Lien, Chang and Hwu 
1998).  In this view, sustained attention deficits measured by CPT have been considered 
as potential vulnerability indicator for schizophrenia (Keri and Janka, 2004). 
 
3.4 Executive functions 
 “Executive functions” refers to a set of cognitive operations on a higher level that are 
essential for the production of goal-oriented behaviour. These skills are necessary to 
generate and execute goal-directed behaviour, especially in novel situations. This 
involves working memory and being able to change actions in response to feedback. 
Executive functions are presumed to be mediated by the prefrontal cortical system 
(Gazzangia, Ivry and Mangun, 2002). The prefrontal cortical system is connected in 
numerous ways to the rest of the brain, which means that executive functions rely on a 
set of less demanding processes. Winsconsin Card Sorting Task (WCST) is one of the 
most commonly used test in this paradigm and tap functions like cognitive flexibility, 
problem solving, rule-learning and maintaining information “on-line”. A great number 
of studies confirm that patients with schizophrenia perform poorer on this test 
(Badcock, Michiel and Rock, 2005). 
 
4.0 Aims of study 
Our main objective was to investigate the association between supplements and 
cognition. We expect a graduation of efficacy on cognitive functions in the following 
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order: 1) combined EPA and antioxidant treatment, 2) a choice of EPA or active 
antioxidants and 3) placebo.   
5. 0 Methods 
 
5.1 Subjects and design 
This study is part of a larger multicentere, double-blind, placebo-controlled trial of 
Ethyl-Eicosapentaenoic Acid (EPA) and antioxidant (vitamins E and C) 
supplementation in the treatment of younger patients with schizophrenia and related 
disorders. The aim of the larger study was to elucidate the effect of adding a 
polyunsaturated fatty acid (eicosapentaenoic acid) and/or antioxidant supplementation 
(vitamin E and C) to neuroleptic treatment of patients.  
 
Inclusion criteria were: 1. diagnoses of schizophrenia, schizophreniform or 
schizoaffective disorder (DSM-IV). 2. Admitted to a hospital/department within the 
previous seven days before screening. 3. Less than six years, in retrospect, since first 
psychotic symptoms (DSM-IV 295, criteria A, 1-4). 4. Age 18-40 years. 5. Speaks 
fluently a Scandinavian language. 6. A written informed consent form must be obtained 
before any trial-related activities. 7. At baseline, significant psychiatric symptomatology 
as shown by either a score of at least 15 on the positive or negative PANSS subscales or 
a total PANSS score (P, N and G subscales) of at least 60.  Exclusion criteria were: 1. A 
diagnose of substance dependence (DSM-IV). 2. Known allergy to study medication. 3. 
Currently taking warfarin or having anamnestic indicators of impaired haemostasis 
(profuse bleeding, except epistaxis). 
 
The patients are selected from hospitals in southern Norway, during an enrolment 
period of one year. The experimental intervention lasted four months. The sample was 
tested at baseline and at week 16. Demographic details are given in Table 1. 
 
     5.2 Neuropsychological assessment 
Both patients and controls completed a broad battery of neuropsychological tests. The 
selected tests assessed attention, working memory, verbal short-term memory and 
executive functions. The battery consisted of the following tests: the Continiuos 
Performance Test IP Version (CPT), the Letter-Number span test (LN-span), the Stroop 
test, the Johns Hopkins Verbal Learning Test (HVLT), the Paced Auditory Serial 
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Addition Test (PASAT), the Letter Fluency Test (phonological association), the 
Category Fluency Test (semantic association) and the Kimura Reccuring Recognition 
Figures Test (Kimura). The Picture Completion test and the Similarities task from the 
WAIS battery were conducted at occasion one as an estimate of IQ.  
 
The tests were administered in a fixed order, though if the administrator observed signs 
of fatigue they were free to administrate them in another order, but as close to the 
original order as possible. The HVLT however, were fixed in all settings because of the 
nature of the tests: HVLT includes a test of recall and recognition 20 minutes after 
reading the list and the test of immediate recall. The CPT was also fixed in all settings 
and was administered in between the two HVLT-tests to maintain a fixed time-ratio for 
all. The administration of the test-battery was completed by five trained research 
assistants. All retest were administered within 17 weeks of the first testing. 
 
2.2.1 Attention 
Tests of sustained attention typically involve the sequential presentation of stimuli over 
a period of time with instructions to the patient to indicate in some way when a given 
target stimulus is perceived. These tasks are generally performed well by persons whose 
capacity for sustained attention is intact (Lezak, Howieson and Loring, 2004). The 
Continious Performance Test IP Version (CPT-IP) (Cornblatt et al., 1989) was selected 
to test sustained attention in this study. Here the subjects had to remove their finger off 
a mouse button when two successively presented stimuli were identical. In the present 
study test number 4 was used consisting of trials with four digit numbers and trails with 
figures. In line with common practice, the performance index reported is the signal 
detection parameter d` (dprime) and β (beta). The sensitivity index, dprime, measures an 
individual’s ability to discriminate target stimuli from non-target stimuli, while the 
response criterion index, beta, is considered an indicator of a patient’s task-taking 
strategy (Liu, Hsieh, Hwang, Hwu, Liao and Lin et al., 2006). Variables irrelevant to the 
intended comparison of sensitivity, such as differences in level of motivation or 
cooperativeness, would yield differences in beta rather than in dprime (Cornblatt and 
Keilp, 1994). Typically, schizophrenia patients and subjects in populations at risk for 
schizophrenia are characterized by lower dprime than controls. On the other hand, these 
populations do not show consistent difference in beta (Cornblatt and Keilp, 1994).  The 
dprime and beta were calculated across all trials and used in the analysis. 
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Stroop tests are based on the findings that it takes longer time to call out the colour 
name of coloured patches than to read words, and even longer to name the colour of the 
ink in which a colour name is printed when the print ink is different than the colour 
name (Dyer, 1973 cited in Lezak, 2004).  The latter phenomena have raised a debate to 
explain this effect. Some argue that the slower response is due to a response conflict, 
while others postulate a failure in selective attention (cited in Lezak, 2004, p.366).  
 
In this study a Norwegian version of the Stroop test (Spreen and Strauss, 1998) was 
used. It includes three subtests: naming colour, reading words and colour and colour-
word. In the colour-word subtest the participants are asked to name the colour of the ink 
the words are written in. Each stimulus in the conflict condition consists of two sorts of 
information; colour words (e.g. green) are written in an incongruent ink colour (e.g. 
blue). The test requires the participants to selectively focus on the ink-information, and 
to ignore the written word. In the analysis, the time used on the conflict condition was 
calculated. 
 
5.2.2 Working memory 
As a measure of the capacity of working memory the Letter-Number span (LN-span) 
(Gold, Arndt, Napoulos, O`Leary, and Andreasen, 1997)3 was chosen. Here the subjects 
are presented with a line of alternating letters and numbers. The subjects are instructed 
to respond by first saying the numbers in order from 1-9, followed by saying the letters 
in alphabetic order. It consists of 24 trials with increasing difficulty (from 2 to 7 items). 
This assess the capacity of working memory because the subjects are given increasingly 
difficult lines of letters and numbers and are then asked to do standard Working 
Memory operation by sorting the information given to them. The capacity increases 
with longer correctly completed strings of items. In the analysis a total of correctly 
completed trails were used. 
 
To assess the attention control of the working memory, a Norwegian version of the 
Paced Auditory Serial Addition Test (PASAT)3 (Spreen and Strauss, 1998) was used. 
This test consists of sixty recorded digits presented to the subject on tape. The digits are 
                                                 
3  Norwegian version by Nils Inge Landrø, University in Oslo. 
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presented in a two second ratio, and are asked to sum the two latest read digits. The 
subject has to respond to the two first digits read, and then taking attention off from 
their own answer, listen to the new digit read, remembering the digit which was read 
prior to their responding, sum them up and give a new response. The total of the correct 
responses was used in the analysis. 
 
5.2.3 Episodic memory 
As a measure of Verbal episodic memory the John`s Hopkins Verbal Learning test 
(HVLT) (Lacritz and Cullum, 1998) was conducted. This is a verbal memory test where 
recall, recognition and learning potential can be measured. The participants are asked to 
remember a list of twelve words. The list is read for the participants three times 
registration of the immediate recall in between. The list items were changed from 
occasion one to occasion two. The selected target variable was overall learning. This is 
a sum score of the three registrations of immediate recall. 
 
5.2.4 Non-verbal memory 
To asses non-verbal memory the Kimura Recurring Figures Test was used. The material 
consists of cards containing either geometric or nonsense figures (Lezak et al., 2004, pp. 
450). The subject’s task is to indicate what item were seen previously. We use a Kimura 
total sum score where false positives are subtracted from the total score to correct for 
guessing.  
 
      5.2.5 Executive functions (fluency tasks) 
The verbal fluency test is used to assess initiation processes and strategies for guiding 
the search for words (Lezak et al., 2004, pp.518). This test compromises two subtests: 
The Letter Fluency Test (phonological association) and the Category Fluency Test 
(semantic association). For the activation task the subjects were instructed to say aloud 
as many words as they could think of beginning with a specified target letter (letter 
fluency; phonological association) or a specified target category (animals, jobs, fruit and 
vegetables). The subjects were asked to produce as many items they could think of 
within the time limit of one minute for each letter/category. A sum score of all words 
generated was used in the analysis. 
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 5.3 Study drugs 
1. Generic name: ethyl eicosapentaenoate 
Trade name: Ethyl-EPA 
Presentation: capsules containing 500 mg ethyl eicosapentaenoate. 
 
2. Generic names:  RRR-α-tochopherol, ascorbic acid 
Trade name: CellaVie (Ferrosan A/S) 
Presentation:  tablets containing 91 mg RRR-α-tochopherol and 250 mg slow relase  
ascorbic acid 
 
      5.3.2 Placebo  
     1. Placebo EPA 
          Presentation: capsules providing 500 mg mineral oil 
 
       2. Placebo antioxidant 
           Presentation: tablets providing dicalciumphosphate (cfr. Ferrosan A/S) 
 
 
5.1.3 Dosage and administration 
The four treatment arms are: 
 Active EPA: 2 g/day delivered as 2 capsules with EPA x 2 (with food), and  
Active antioxidants: RRR-α-tochopherol 364 mg and ascorbic acid 1000 mg a day, 
delivered as 2 tablets x 2 (with food). 
      Active EPA: 2 capsules x 2 ; placebo antioxidant: 2 tablets x 2. 
     Active antioxidant: 2 tablets x 2; placebo EPA: 2 capsules x 2 
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Placebo EPA: 2 capsules x 2; placebo antioxidant: 2 tablets x 2    
 
      5.5 Statistical analyses  
The statistical tests were carried out using the Statistical Package for the Social Sciences 
(SPSS, version 12.0). The significance level was set at p≤0.05 for all analyses. 
 
To analyse differences between patients and healthy controls in demographical data, a 
Pearson`s Chi-Square or Fisher’s exact test were used for categorical variables. For the 
remaining variables independent two-sample t-tests were used. To analyse group 
differences on cognitive test scores, a t-test was used (Table 2). 
 
Missing data is an important issue for analyzing and interpreting results, especially in 
clinical groups. Patients with schizophrenia have a high drop-out rate in follow-up 
studies, and this entails a high proportion of missing data. The appropriate model for 
analyzing will be a Linear Mix Model that takes in consideration the unbalanced nature 
of longitudinal data and which explores both fixed and random effects. The pattern of 
missing data is not known on forehand, and these data will therefore be treated as 
randomly distributed (Tu, Zhang, Kowalski, Shults, Feng and Sun et al., 2006).  
 
We used the Linear Mixed Model (LMM) programme to analyse longitudinal effects. 
We examined the effect on neurocognitive tests of time, treatment groups and baseline 
PUFA. Time was coded (0,1), and treatment categories were EPA (0,1) and antioxidants 
(0,1). PUFA was a continuous variable (referred to as “omegasum” in the tables), (≥ 0 
µg/g Red Blood Cells). 
 
“Subject” (intercept) was treated as the only random effect. The fixed effects were 
intercept, time, time x EPA, time x antioxidants and time x EPA x antioxidants in the 
model. Placebo and active treatment groups were assumed to be equal by design as for 
the outcome variable at baseline, because allocation to treatment groups was random. 
Thus the main effects of EPA and antioxidants were not included in the statistical 
model. In the model adjusted for a moderator (baseline PUFA), fixed effects of PUFA, 
time x EPA x PUFA, time x antioxidants x PUFA and time x EPA x antioxidants x 
PUFA were added to the raw model.  
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Data imputed in General Linear Model (GLM) (figures) from Linear Mixed Model 
analyses (SPSS 12.0). p-values: LMM moderator (PUFA at baseline) has been centered 
on typical patients from whole group, low and high groups, resepctively; whole sample 
(n=49) used. In order to display the results graphically, the GLM programme (SPSS 
12.0) had to be used. Values for the dependent variables predicted by LMM replaced 
missing values in GLM analyses. In GLM analyses, adjustment was done for baseline 
dependent variables in order to have the same point departure for the treatment options 
in each figure. 
 
6.0 Results 
 
6.1 Demographical and psychometric characteristics 
There were significant differences between the patients and controls in age, sex and 
education (Table 1). Both groups completed the Similarities and the Picture Completion 
test, which is part of the WAIS battery and from which an IQ-score can be roughly 
estimated, as the first test is highly correlated with verbal IQ and the second with non-
verbal IQ.  The patients scored significantly below the controls on both tests, as can also 
be seen in Table 1. 
 
Table 1 
Mean and S.D of demographic variables for the patients and the controls and t-test of 
the difference between the groups 
 Patients (n=53) Controls (n=20) 
Age (years) 26.2 (5.0) 31.1 (5.3) *
Education (years) 11.7 (1.9) 14.6 (1.5) *
Gender (m/f) 37/16 11/9 
Doi (years) 3.9 (3.7) ----
Similarities¹ 9.0 (2.8) 11.7 (2.5) *
Picture completion¹ 7.8 (3.0) 11.8 (2.9) *
Doi =Duration of illness       ¹Both tests are part of WAIS battery                   * p<0.05 
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Retrospective analysis of the whole trial sample (n=99) showed that the concentration of 
polyunsaturated fatty acids in red blood cells at baseline was bimodally distributed 
(Bentsen, Solberg and Lingjærde et al., in prep 2007). It has been shown statistically 
that the sample can be divided in two groups according to the patients PUFA levels: a 
high PUFA group (> 137µg/g RBC) and a low PUFA group (≤ 137µg/g RBC) as seen in 
figure 2. 
 
Figure 2 Distribution of RBC polyunsaturated fatty acids in all patients at baseline (n=99) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     6.2 Cognition 
 
a) Comparison between patients and healthy controls 
 
The mean neuropsychological test scores for the patients and the controls and a t-test of 
the group differences at baseline are presented in Table 2. As expected, the overall 
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performances of the clinical groups were below the control groups. The controls 
perform significantly better on all tests than the patients, except for the CPT beta and 
Kimura. 
 
Table 2 
Mean and S.D. of the neuropsychological test scores for the patients and the controls 
and t-test of the difference between the two groups at baseline. 
 Patients (n=53) Controls (n=20) Significance 
Attention  
CPT dprime 1.2 (0.5) 2.0 (0.6) <.001
CPT beta 2.1 (1.5) 1.7 (0.8) n.s.
Stroop conflict 59.3 (19.7) 43.2 (7.2) <.001
Working memory  
LN span 11.6 (3.5) 14.6 (3.6) .008
PASAT 37.9 (14.2) 50.7 (8.5) <.001
Episodic memory  
HVLT 20.3 (6.7) 27.0 (3.8) <.001
Non-verbal memory  
Kimura 22.3 (7.3) 24.7 (6.5) n.s
Executive functions 
(fluency tasks) 
 
 
Phonological fluency  18.2 (8.1) 24.1 (8.7) .008
Semantic fluency 31.6 (9.5) 45.3 (8.5) <.001
 
 
 
b) Effects of treatment in the patient group 
 
The effect of trial drugs was analyzed by the standard adjusted LMM on the following 
cognitive functions: verbal episodic memory (Hopkins), attentional control of working 
memory (PASAT), capacity of working memory (Letter-number span), phonological 
fluency (The Letter Fluency Test), semantic fluency (The Category Fluency Test), 
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sustained attention (CPT, dprime), selective attention (Stroop, conflict; time) and non-
verbal memory (Kimura). Attention turned out to be the only domain affected (CPT 
dprime and Stroop) by trial drugs. The standard adjusted LMM analyses showed only 
significant effects of antioxidants on Stroop conflict time and of EPA on CPT dprime. 
Both were moderated by the level of baseline PUFA, thus the effect was less beneficial 
or more harmful the lower the PUFA. We selected these attention variables for further 
LMM analyses of the effect of healthy control-patient status and time (Table 3 and 4).  
 
Table 3 shows that EPA impaired the course of CPT dprime over the trial (p=0.02), but 
this effect was positively modified by the PUFA level at baseline (p=0.02). Thus, the 
lower the PUFA, the less beneficial was the effect of EPA on the course of CPT.  There 
was no effect of antioxidants on the course of CPT. However, the effect of EPA was 
positively modified by antioxidants (p=0.03). Thus, combining EPA and antioxidants 
entailed a beneficial effect on CPT compared to placebo or one supplement alone. 
 
Table 3 
Estimates of Fixed Effects 
Parameter Estimate 95% Confidence Interval Sig. 
Intercept 1.10 .76 -1.45 .000
Time .33 .10 - .56 .006
EPAgroup x Time -.56 -1.03 - -.10 .019
Antiox.group x Time -.07 -.71 - .58 .832
EPAgroup x Antiox.group x Time 1.2 .12 – 2.29 .031
Omegasum* .000 -.000 - .002 .481
EPAgroup x omegasum* x Time .002 .000 - .003 .021
Antigroup x omegasum* x Time .000 -.003 - .004 .904
EPAgroup x Antiox.group x 
Omegasum* x Time 
-.004 -.008 - .001 .143
Dependent Variable: CPT dprime (attentional sensitivity). *Omegasum = PUFA level at 
baseline. 
 
 
Table 4 shows that antioxidants impaired the course of the Stroop test over the trial 
(p=0.01), but that this effect was negatively modified by the PUFA level at baseline 
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(p=0.008). Thus, the lower the PUFA, the less beneficial was the effect of antioxidants 
on the course of the Stroop test. Antioxidants or combining the trial drugs did not have 
any effect on the course of the Stroop test.  
 
 
 
Table 4 
 
Estimates of Fixed Effects 
Parameter Estimate 95% Confidence Interval Sig. 
Intercept 21.34 12.18 – 30.50 ,000
Time 2.66 -8.55 – 13.87 .64
EPAgroup x Time -6.65 -29.81 – 16.50 .57
Antiox.group x Time 35.22 8.09 – 62.36 .01
EPAgroup x Antiox.group x Time -26.64 -76.03 – 22.74 .29
Omegasum* .009 -.024 - .04 .59
EPAgroup x Omegasum* x Time -.002 -.076 - .07 .95
Antiox.group x Omegasum* x Time -.15 -.26 - -.04 .008
EPAgroup x Antiox.group x 
Omegasum* x Time 
.15 -.04 - .33 .12
Dependent variable: Stroop Conflict.                         *Omegasum = PUFA level at baseline. 
 
The effects of trial drugs in the low versus high PUFA groups are illustrated in figures 
3-4. The significant levels refer to the statistical models shown in table 3-4, but the 
“omegasum” (= PUFA at baseline) have been centred on the median PUFA of the whole 
sample and the mean PUFA levels in the high and low PUFA groups respectively. Thus, 
p-values correspond to treatment effects according to LMM for the typical patient (as 
for PUFA level) in these samples.  
 
Figure 3 illustrates the whole group and the two PUFA groups performance on CPT. 
Significant results is observable for the low PUFA group receiving only EPA (p=0.03). 
This shows that the single EPA group decrease performance on CPT. Significant 
(p=0.03) result were also found in the low PUFA group receiving the combination 
intervention (EPA and vitamin E + C). Here, on the other hand, performance on CPT 
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increased. In comparison to the placebo group there was a non-significant beneficial 
effect on CPT dprime of the combined treatment in the low PUFA group (p=0.15).  
 
Figure 3: Continuous Performance Test dprime
Effects of EPA alone or EPA and Vitamins E+C combined
Whole group (n=49) High PUFA (n=33)Low PUFA (n=16)
p=0.41
p=0.57
p=0.03
p=0.03
p=0.78
p=0.93
p=0.03
p=0.14
 
 
Figure 4 illustrates the whole group and the two PUFA groups performance on Stroop. 
Significant results (p=0.007) were obtained in the low PUFA group receiving vitamin E 
and C. This shows that the low PUFA group receiving only antioxidants reduces their 
performance on the Stroop. 
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Figure 4: Stroop conflict time, effects of vitamins E+C alone
p=0.41
p=0.007p=0.74
p=0.01
p=0.76
Whole group (n=49) Low PUFA (n=16) High PUFA (n=33)
      7.0 Discussion 
The purpose of this study was to investigate the effect of an omega-3 fatty acid (EPA) 
and antioxidants (vitamin E and C) on cognitive functions in people with schizophrenia. 
To our knowledge, this randomized, double-blind, placebo-controlled study is the first 
to be executed on the effects of EPA and antioxidant supplementation as treatment for 
cognitive deficits in schizophrenia. The only way to verify whether EPA and 
antioxidants are potential therapeutic options in the management of cognitive functions 
in schizophrenia is to conduct large randomized controlled trials similar to those 
required for the licensing of any new pharmacological treatment, as we have done here.  
 
We expected that the group that received double supplements would perform better on 
the cognitive tests after 16 weeks, than the groups who received single supplements or 
placebo. That is, we expected a graduation of efficacy in the following order: 1) 
combined EPA and antioxidant treatment, 2) EPA in combination with placebo 3) 
antioxidants in combination with placebo and 4) double placebo. We assumed that the 
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addition of antioxidants to EPA would reduce oxidative stress and reinforce the effect of 
EPA. Oxidative stress is considered to have a negative effect on the neuronal 
membranes and furthermore affect the CNS through maladaptive neurotransmitter 
communication and neurodevelopment. In turn, this is associated with lower cognitive 
performance (Mahadik and Yao, 2006). We anticipated this outcome in individuals with 
schizophrenia because they are thought to have an altered cell- metabolism, and an 
impaired antioxidant defence system (AODS) which makes them more vulnerable to 
oxidative stress (Mahadik, 1994).  
 
Overall, the results did not confirm our expectations concerning the graduation of 
efficacy. Hence, we did not find a positive link between cognitive performances and the 
adjunctive use of fatty acids and antioxidants. The significant results we obtained were 
negative in that performance on attention variables was decreased and this effect was 
restricted to the groups receiving single supplement groups. The EPA-group performed 
poorer on CPT, while the antioxidant-group performed worse on the Stroop-test. The 
performances on the rest of the cognitive tests were not influenced by the trial drugs or 
placebo.  
 
We also looked at retrospective analyzes from the larger study (Bentsen et al. in prep, 
2007). These analyzes reveals a division of patients in a high and low PUFA group as 
measured by PUFA levels in red blood cells (Bentsen et al. in prep. 2007). These levels 
show a bimodal distribution, where one of three patients had very low levels of PUFA`s 
compared to healthy controls (Bentsen et al. in prep. 2007).  In line with this, earlier 
studies have shown PUFA levels to be bimodally distributed among patients with 
schizophrenia (Glen, Glen, Horrobin,Vaddadi, Spellman and Morse-Fisher et al.,1994; 
Peet, Laugharne, Rangarajan, Horrobin and Reynolds, 1995). This is suggested to 
reflect a metabolic abnormality of aetiological importance (Peet et al.,1995). 
 
The interesting aspect of the bimodal distribution in PUFA levels is that these are 
related to cognitive performance. Stroop was only affected in the low PUFA group 
when the antioxidants were given alone, while CPT was only affected in the low PUFA 
group when EPA was given. Antioxidants increased the time on Stroop and the 
unfavorable effect was also significantly higher in the low- than in the high PUFA 
group. Similar results were obtained for the CPT when receiving EPA. EPA reduced the 
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CPT dprime, and the effect was also restricted to the low PUFA group. The higher the 
PUFA, the less was this disadvantageous effect. Hence, low PUFA levels were linked to 
poor attentional performance. The low PUFA group receiving both interventions 
demonstrated the only combination effect (increased performance on CPT), that we on 
forehand expected for all groups and tests, although this effect was non-significant to 
placebo treatment. The combination effect was not observable in the first analyses, 
probably because it was diminished when the patients (and hence the difference in 
PUFA-levels) were mixed. 
 
The failure of EPA to produce cognitive improvement in patients with chronic 
schizophrenia in the study by Fenton et al. (2001, op.cit.pp.12) has several possible 
explanations. To begin with, the dose of EPA is not optimal. Peet and Horrobin (2002) 
conducted a study of patients with schizophrenia in where placebo was compared with 
different doses of EPA. The best results were achieved at the 2g/day dose, which 
produced an increase in red cell EPA without any decrease in red cell AA, which would 
be unfavourable. Fenton et al. (2001) may have used too high EPA (3g/ day) doses that 
depleted AA fatty acids. Based on these findings 2g/day dose was used in the current 
study. Additionally, Fenton et al. (2001) based their study on the exploratory interest of 
improving cognitive functions since fatty acids have shown to relief symptoms, and did 
not ground the trial on the theory of oxidative stress. However, this study was developed 
with respect to explore the mechanism of oxidative stress and therefore prompted use of 
high-dose antioxidants, in contrast to Fenton et al. (2001). This study also used a 
combination of vitamin E and C for optimal reduction of oxidative stress. This is 
believed to provide complete antioxidant defence because the potency of vitamin E is 
maintained by vitamin C. Besides this, age and illness duration have implications for the 
effectiveness of the interventions. Fenton et al`s (2001) subjects had a higher mean age 
and duration of illness than our participants. Fenton et al. (2001) also had an insensitive 
design, lacking a control group.  
 
Taken together, the analyses show that 1) single antioxidant- or EPA supplementation 
impaired attention variables in the low PUFA groups and only in these groups, 2) it 
reveals a bimodal distribution of PUFA levels and 3) the combination effect was only 
evident in the CPT test in the low PUFA group when the patients were divided in 
groups according to PUFA-levels, but not significantly superior to placebo. 
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     7.2 Attention as a vulnerability marker in schizophrenia 
Abnormalities in attention have long been viewed as one of the fundamental underlying 
cognitive deficits in schizophrenia and are likely to contribute both to formation of 
some types of symptoms and particularly to the substantial work and social impairments 
that often follow schizophrenia (Nuechterlein, Pashler and Subotnik 2006).Yet, the 
precise nature of the attentional deficits in schizophrenia remains poorly understood. 
Attention is generally regarded as a complex and comprehensive concept and there 
might only be specific aspects of the attention-construct that are deficient in 
schizophrenia. The network assumed to underlie the distribution of attention in the brain 
involves structures in all lobes, including subcortical regions (Posner, 1994). This 
network is also very specific to certain aspects of attention, something that can be 
demonstrated through variation in attention deficits that are seen in cases of brain 
damage.  
 
The CPT-IP is by many researchers regarded as a vulnerability-marker of schizophrenia 
because studies demonstrate that it consistently discriminates affected patients from 
controls (Francey, Jackson, Phillips, Wood, Yung and McGorry, 2005). Simultaneously 
the impairment of sustained attention, as measured by the CPT, is seen in the healthy 
first-degree relatives of patients with schizophrenia (Chen et al., 2004) and the deficit 
appears independent of clinical symptoms (Wang, Chan, Sun, Yao, Deng and Sun et al., 
2006). Also, the reaction-time of the CPT is suggested as an endophenoytpic marker for 
schizophrenia (Wang et al., 2006). These findings support the notion that sustained 
attention is a susceptibility indicator for schizophrenia. It is especially genetic 
researchers that advocate this point of view, highlighting the link between biology and 
cognition (Mahadik and Yao, 2006). The CPT being such a sensitive test might detect 
subtle biological alterations in a larger degree than other tests are able to register, which 
contribute to explain our findings. Generally, the CPT-IP is a difficult task and the EPA 
given could have changed the biological machinery in means that have enlarged the 
already existing deficit. This means that the EPA might have influenced neurobiological 
variables essential for certain attentional capabilities (e.g. processing capacity), which 
are traced by the CPT-IP. Moreover, the observed attentional deficit appears to 
represent a true impairment in processing capacity rather than a group difference in 
response style or motivation, as our participants did not differ from the control group on 
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the beta variable. Attributing lower performance to motivational factors is therefore 
ruled out (for a detailed review of the signal detection paradigm, see Appendix, 10.2).  
 
The CPT is also regarded as a measure of working memory because stimuli must be 
held “online” in order to determine when to respond (Thaden, Rhinewine, Lencz, 
Kester, Cervellione and Henderson et al., 2006). Still, tests of working memory used in 
this study (PASAT and LN-span) were not affected in any of the groups. Attention, as 
measured by CPT, requires less maintenance of internal representations and 
consequently have smaller load on working memory. Hence, the CPT is conceptualised 
as a more basic measure of attention. This illustrates the nuances captured by the 
different tests and support specific attentional deficiencies in schizophrenia. We propose 
that abnormalities in the development of circuits that subserve specific aspects of 
attention may be central to the pathopyhsiology of schizophrenia and that these deficits 
are perceptible via the CPT-IP. 
 
The Stroop test is the second cognitive tests affected negatively in our study. The 
phenomenon of a markedly slow naming response when a colour name is printed in ink 
of a different colour has received a variety of interpretations (Lezak et al., 2004, pp. 
366). Some have attributed the slowing to response conflict, some to failure of response 
inhibition, and some to a failure of selective attention. This is one example of why it is 
difficult to make inferences about what specific effects the antioxidants have. Like in 
the CPT we suggest that the supplements affect specific, perhaps more vulnerable parts, 
of the attentional network. As in the CPT-IP, decreased performance may be caused by 
unfavourable changes in the biological environment and therefore reflects a slowed rate 
of information processing. However, since this reduction in performance only concerns 
the low PUFA group, the results may be best understood in the light of vulnerabilities 
following this group. For instance can their distractibility threshold be lower than in the 
high PUFA group. 
  
A shared characteristic of CPT and Stroop is that they require inhibition of a pre-potent 
response (Lezak et al., 2004). This is a process that demands more capacity than 
automatic processes, and therefore requests more cognitive flexibility. Anterior 
cingulate cortex (ACC) is indicated in the process of controlling and correcting 
responses, and is considered to be a vital contributor to the inhibition of pre-potent 
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responses (Gazzagnia et al., 2002). Attentional deficits in schizophrenia have in part 
been ascribed to impairment of the ACC (Yücel, Pantelis, Stuart, Wood, Maruff and 
Velakoulis et al., 2002). The anterior cingulate in patients with schizophrenia is for 
instance less activated during Stroop task performance (Carter, Nichols and Cohen, 
1997). The decreased performance on CPT and Stroop can be a way of adjusting to a 
saccade of biological events that is initiated by the adjunctive use of fatty acids or 
antioxidants. Still, why ACC should be particularly influenced is unclear.  
 
In summary, we found that impairments in attentional performance using the CPT-IP 
and Stroop become more pronounced when receiving one of the supplements, but only 
in the low PUFA groups. We also found an increase in performance on the CPT in the 
group receiving double supplements, also limited to the low PUFA group. This 
combination effect was not observable in the Stroop test. In sum, these tests seem to be 
linked to particular attentional constitutional aptitudes, whose relations with the 
supplements are yet to be explained. Furthermore, CPT-IP is confirmed to be a sensitive 
measure in detecting subtle cognitive alterations. 
 
      7.3 Interpretations of results 
We argue that the beneficial combination effect on CPT in the low PUFA group can be 
explained by the characteristics tied to the low PUFA levels and the sensitivity of CPT. 
The combination intervention can exert most effect in the low PUFA group and may 
first be noticed by CPT.  Our hypothesis is therefore that the low PUFA group has 
greater benefit from reduction of oxidative stress and the adding of both PUFA and 
antioxidants. The non-significant beneficial effect of the combined treatment on CPT 
compared to placebo can be due to low statistical power. There is also reason to believe 
that this effect may prove superior to placebo in a larger sample (e.g. 100), as we 
observe a beneficial tendency.  
 
Why our aims in general were not supported might be due to a variety of factors:  
Firstly, the heterogeneity of schizophrenia might confound data and make it difficult to 
reveal larger effects (Zielasek, Ehlis, Herrmann and Fallgatter, 2004). Secondly, it 
might take longer time than 16 weeks to have an effect on the cognitive stage. 
Correcting abnormal cerebral PUFA levels can take more time than correcting PUFA in 
red blood cells because they have a high turn over. Thirdly, the link between cell 
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function and cognitive function is multifaceted and not linear (Mahadik et al, 2001). It 
might be other steps “on the way” between the cell-level and cognitive level that is 
maladaptive or aberrant (e.g. brain-structures or functional connectivity) that the 
reduction of oxidative stress can not modify. Fourthly, the lack of positive results might 
be because fatty acids and antioxidants have a primary preventive role of developing 
schizophrenia and not in the treatment of manifested cognitive deficits. It is possible 
that when a disease is clinically apparent, the neuropathological involvement is too 
advanced to be substantially attenuated by reduction of oxidative stress. It may also be a 
more fundamental abnormality in the cell membrane and -metabolism in schizophrenia 
which is more difficult to correct than by nutritional intervention. Fifthly, it is possible 
that the use of adjunctive supplements is ineffective; either we were not able to reduce 
the oxidative stress, or this process is not as closely tied to cognitive functions in 
schizophrenia like we assumed. Also, due to the lack of guidelines from past research in 
shaping our hypothesis, it is possible that the formulation of expectations prevented us 
from observing a relationship. For instance, findings regarding reduction of symptoms 
when patients receive fatty acids (Mahadik, et al., 2006; Laugharne, et al., 1996,) or 
antioxidants (Dakhale, et al., 2005) do not have to be transferable to cognitive 
improvement. Alternatively, the fact that we do not get a positive effect of EPA might 
indicate that the type of PUFA (i.e. the different therapeutic effects of DHA EPA or 
AA) is not the crucial part to raise change in cognition. EPA is not a major membrane 
fatty acid and levels of its metabolites, such as eicosanoids, may increase at high doses. 
These metabolites have shown to have some unwanted effects (Mahadik et al., 2006) 
and the lack of knowledge about EPAs side effects might contribute to why we get 
reduced performance on attention in the EPA group with low PUFA. Finally, the 
statistical power is low, entailing high risk of type ΙΙ error.  
 
There are several ways to conceptualise the findings of a bimodal distribution of PUFA 
levels in our patient group. It indicates that the sample is not homogenous and may 
reflect two distinct disorders. This result accompany the debate concerning the validity 
of the schizophrenia diagnose (Malt et al., 2003; Green, 2004). That is, although the 
international diagnostic systems are valid for clinical diagnostic purposes, it might be 
insufficient for the aetiological research of schizophrenia (Reddy et al.,). Moreover the 
distribution can give support to the theoretical view of conceptualising schizophrenia in 
a dimensional perspective (e.g. schizotaxia). We suggest that the PUFA-level can 
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represent an aspect of a biological susceptibility for developing variations of illnesses in 
the schizophrenia spectrum. Hence, the liability can be expressed in a larger or lesser 
degree and end up as diagnosis with differences in course and outcome. This way we 
also see how the diathesis-stress framework (op.cit. pp. 4) of schizophrenia is 
significant (Jones and Fernyhough, 2006). There might be tied different characteristics 
to the differences in PUFA-levels that are specific to the subgroups; this could involve 
maladaptive absorption of nutrients and/or a difference in cell metabolism, or reflect 
variations in stress-tolerance Furthermore, the expression of this diathesis can depend 
on e.g. stress exposure, diet and pro-oxidant behaviour. Since the negative effect only 
concerns the low PUFA groups in our study, it may be certain vulnerabilities related to a 
low level of PUFA, or protective factors tied to the high PUFA group. PUFA levels 
might therefore predict different prognosis in terms of aetiology, symptoms and course.  
 
Another concern regarding the low and high PUFA levels is to ascertain whether the 
PUFA level is transient or a stable trait (Mahadik et al., 1994; Reddy et al., 2004). If 
differences in PUFA levels characterize stable traits of schizophrenia, and not just 
transient states associated with for example psychosis, they would be valuable in 
clinical practise and as a biological marker for the disorder. Reddy et al., (2004) who 
investigated 24 neuroleptic-naive patients with first episode schizophrenia or 
schizoaffective disorder, found that relative to normal subjects, patients had significant 
reductions in total PUFA. These reductions were not related to age, gender, smoking 
status, or nicotine levels. They interpret this as supports to that significant PUFA 
reductions occur early in the illness, prior to initiation of treatment, and raise the 
possibility that these deficits are trait related.  
 
These findings points to a biological abnormality manifested as low PUFA levels that 
seem specific to a subgroup in schizophrenia. The differences can elucidate information 
about variations in pathophysiology. Identifying a biological marker within the clinical 
group of schizophrenia may yield information about endophenotypes and guide research 
on good prognostic variables further. We do not claim that the PUFA level is the cause 
of cognitive dysfunction in schizophrenia, rather that the wide range of genetic and 
environmental influences contributing to the disorder may operate through different 
pathways. What biological abnormality that precedes the division in PUFA-levels is yet 
to be elucidated. We have simply revealed that the group with this “trait” do not profit 
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on the adjunctive use of fatty acid and antioxidants taken alone. It can also reflect a trait 
impairment of schizophrenia independent from symptom profile, but we have not 
focused on symptoms here.   
 
It is vital to identify the best timing to start the adjunctive use of supplements. The 
schizophrenia pathology can occur at all stages and might influence each other in the 
process of developing the illness. Therefore it is a complex question to answer when the 
supplements will exert most effect. Timing may be one of the reasons why we do not 
obtain positive results in our study. It can exist critical periods for remodelling the 
neuronal membrane pathology. If the pathology occur at an early stage, it is reasonable 
to think that it is reinforced later in life, but can profit on supplements. Further, the 
growth of the pubertal brain increases the process of oxidative stress for individuals 
having an abnormal cell metabolism. Adolescence may be an especially sensitive period 
where supplement can make a difference. For example it is proposed that there is 
increased “pruning” (excessive removal of nerve endings and processes during pubertal 
maturation) as a result of oxidative injury (Keshavan, Anderson and Pettegrew, 1994). 
The results hold up that little is known about the pathologic progression from an at-risk 
state to clinical disease, and which set of processes takes over at some point to cause 
progression of clinical disease. We believe that oxidative stress is of importance here, 
but the complexity of our results demonstrates the intricacy of this field.   
       
     7.4 Limitations and suggestions for further studies 
One of the objections to our study concerns the uptake of supplement. Some studies 
show that the effect of antioxidants is better obtained from in natural forms, than from 
capsules. It has for example been demonstrated that vitamin E in its natural forms 
protects better against lipid peroxidation than E-vitamin pills (Wolf, 1997). Therefore 
the power of supplements might be weaker when administered as a capsule. Moreover, 
to find out if oxidative stress is the mechanism behind the altered cell metabolism in 
schizophrenia, the field is in need for better measures. Methods to date can not ensure 
the validity of measures we use to assess oxidative stress. 
 
Another limitation is the lifestyle characteristics typical for patients with schizophrenia, 
involving much pro-oxidant behaviour, like fast –food consumption, alcohol- and 
marihuana intake and cigarette smoking (Hibbeln, Makino, Martin, Dickerson and 
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Fenton, 2003; Mahadik and Yao, 2006). Besides this, the pro-oxidant qualities of the 
atypical antipsychotic medications can additionally increase the oxidative cell injury. 
Antipsychotics can alter oxidative stress by changing antioxidant defence systems and 
generating reactive oxygen species (Mahadik and Yaho, 2006). Some anti-cholinergic 
drugs are prone to cognitive deterioration, and older neuroleptica (e.g. Haloperidol) has 
a toxic effect on the neuronal membranes and act as a pro-oxidant. Some newer 
neuroleptica on the other hand, avoids this effect (e.g. Olanzapine, Clozapine). These 
factors will influence the results when investigating supplement interventions.  
 
Moreover, the stability of patients might be a factor to control for in further studies. We 
could have obtained different results if we started the intervention at a more stable phase 
than when acutely hospitalised. Differences in symptoms, length of prodromal phases 
and illness-onset vary considerably and may contaminate the data. Further studies 
should aim to select samples that are as similar as possible on these variables. Although 
schizophrenia is hard to study because of high drop out, further studies should aspire 
lager samples to increase the statistical power. In relation to the missing data caused by 
drop outs, LMM analysis should be used.  
 
Subsequent studies must also consider the use of first-degree relatives of schizophrenia 
patients. This is of relevance because they are one type of at-risk population for 
developing the illness. Such subjects are optimal for studying the biological 
mechanisms involved in schizophrenia, since they are free of the confounding variables 
that are common in research with schizophrenia patients (like drugs and psychosis). 
Investigating PUFA levels in these relatives will clarify how cognition and oxidative 
stress is involved in the pathogenesis of the illness.  
 
Overall, our findings cannot serve as basis for general recommendation for cognitive 
treatment of dietary supplementation of fatty acids and antioxidants in patients with 
schizophrenia. But it is important to emphasize that the negative effect on dprime and 
Stroop in the single- supplement groups are eliminated when the supplements are given 
together in the low PUFA group. This underscores the importance of defining patients 
PUFA level. The low PUFA group experiences a negative effect of single supplements 
and we also believe that they are more sensitive to other interventions. For this reason, 
ethical aspects should be considered in future studies. 
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Taken together, further studies should conduct larger, randomized, placebo-controlled 
trials. In these trials varieties of fatty acids, antioxidants and different and daily doses 
should be compared. They should select younger patients at a stable phase and divide 
them initially by measuring the PUFA levels and follow the different effects on 
cognitive variables closely. Repeating studies on the PUFA subgroups adding genetic 
information is of major interest. This way one can better come around the heterogeneity 
of schizophrenia and investigate the effects of supplements on different subgroups that 
react very differently to the adjunctive use of EPA and antioxidants. 
 
8. Conclusion  
This study validates earlier findings of cognitive deficits in schizophrenia and that they 
cover a broad range of functional areas. However, the current study does not reveal a 
consistent relationship between supplements and cognitive functions in younger patients 
with schizophrenia spectrum disorders. The study holds up attention as a vulnerable 
psychological construct, and CPT and Stroop as sensitive measures that are able to 
detect subtle cognitive changes. Furthermore, a bimodal distribution of PUFA levels 
was disclosed and linked to performance on these attentional parameters. The 
combination effect of the supplement improved attentional function in patients with low 
PUFA levels, although this beneficial effect was not significant compared to the placebo 
group. 
 
The bimodal distribution of PUFA levels give support to the heterogeneity of 
schizophrenia. This might contribute to explain why research in this field has been 
inconsistent and delayed; one may actually overlook important biological parameters by 
putting together patients from different subgroups. The finding also has implication for 
clinical practice as initial measure of PUFA levels in patients with schizophrenia could 
contribute to therapeutic improvement. The study also illustrates the complexity of 
drawing a line from biological structures, like neuronal membranes, to cognition and 
behaviour. Our result does not establish that oxidative stress is the crucial aspect of 
cognitive deficits in schizophrenia, but provides a valuable theoretical standpoint for 
further exploration of diet supplementation as a new therapeutic strategy.   
 
 
 40
8.0 References  
 
American Psychiatric Association (1994). Diagnostic and statistical manual of mental 
disorders (DSM-IV). 4th ed. Washington: The Assosciation. 
 
Addington, J. (2000). Cognitive functioning and negative symptoms in schizophrenia. In T. 
Sharma and  P. Harvey (Eds.), Cognition in schizophrenia (pp. 193-209). New York: 
Oxford University Press. 
 
Adler, L.A., Rotrosen, J., Edson, R., Lavori., P., Lohr, J., Hitzemann R. and et al. (1999). 
Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry, 56, 836-841. 
 
Arvindakshan, M., Ghate, M., Ranjekar, K.R., Evans, D.R. and Mahadik, S.P. (2003). 
Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) 
Improves the outcome of schizophrenia. Schizophrenia research, 62, 195-204. 
 
Assies J., Lieverse, R., Peter, V., Wanders, R.J.A., Dingemans P.M.J.A. and Linsezen D.H. 
(2001). Significantly reduced level of docosahexaenoic acid and docosapentaenoic acid in 
erythrocyte membranes from schizophrenia patients compared with a carefully matched 
control group. Biological Psychiatry, 47, 8-21. 
 
Austin, J., (2005). Schizophrenia: An Update and Review. Journal of Genetic Counceling, 
14, 329-340. 
 
Badcock, J.C., Michiel, P.T. and Rock D. (2005). Spatial working memory and planning 
ability: contrasts between schizophrenia and bipolar 1 disorder. Cortex, 41, 753-63. 
 
Belger, A. and Dichter, G. (2006). Structural and functional neuroanatomy. In Lieberman, 
J.A., Stroup, T.A. and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.167-185), (1st 
Ed.). The American Psychiatric Publishing. 
 
Bentsen, H., Solberg, D.K., Lingjærde, O. et al., (2007). Clinical effects of adding ethyl-
EPA and/or vitamins E and C to antipsychotics drugs in schizophrenia and related 
disorders: A Norwegian randomized placebo-controlled trial. Paper in preparation.  
 41
 
Borg, N.E. and Rund, B.R. (1999). Kognitiv trening av pasienter med schizofreni. In 
Borchgrevink, T., Fjell, A., and Rund, B.R. (Eds.). Psykososial behandling av psykoser ved 
schizofreni. (Psychosocial treatment of psychosis in shizophrenia) (pp 261-269), (2nd Ed.) 
Tano Ashehoug. 
 
Bowie, C.R. and Harvey, P.D. (2006). Treatment of cognitive deficits in schizophrenia. 
Curr Opin Ivestig Drugs, 7, 608-613. 
 
Breitborde, N.J., Lopez, S.R., Wickens, T.D., Jenkins, J.H., and Karno, M. (2007).Toward 
specifying the nature of the relationship between expressed emotion and schizophrenic 
relapse: the utility of curvilinear models. International Journal of Methods in Psychiatric 
Research, 16, 1-10 
 
Carter, C.S., Mintun, M., Nichols, T. and Cohen, J.D. (1997). Anterior cingulated gyrus 
dysfunction and selective attention deficits in schizophrenia: [15O]H2O PET study during 
single-trial Stroop tak performance. American Journal of Psychiatry, 156, 1670-1675. 
 
Chaturvedi, S. and Thakur, R. (2003). Neuropathology of schizophrenia—a review. Indian 
Journal Pathology & Microbiology, 46, 165-169. 
 
Chen, W.J., Chang, C.H., Liu, S.K., Hwang, T.J. and Hwu, H.G. (2004). Sustained attention 
deficits in non-psychotic relatives of schizophrenic patients: a recurrence risk ratio analysis. 
Biological Psychiatry, 55, 995-1000.  
 
Chen, W.J., Liu, S.K., Chang, C.J., Lien, Y.J., Chang, Y.H. and Hwu, H.G. (1998). 
Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of 
schizophrenic patients. American Journal of Psychiatry, 155, 1214-1220. 
 
Christensen, O. and Christensen, E. (1988). Fat consumption and schizophrenia. Acta 
Psychiatrica Scandinavica, 78, 587-591. 
 
Compton, M.T. (2004). Considering schizophrenia from a prevention perspective. 
American Journal of Preventive Medicine, 26,178-85. 
 42
 
Cornblatt , B.A. and Keilp, J.G. (1994). Impaired attention, genetics and the 
pathophysiology of schizophrenia. Schizophrenia Bulletin, 20, 31-46. 
 
Cornblatt, B.A., Lenzenweger, M.F. and Erlenmeyer-Kimling, L. (1989). The Continuous 
Performance Test Identical Pairs version: ІІ. Contrasting attentional profiles in 
schizophrenia and depressed patients. Psychiatry Research, 29, 65-85.  
 
Dakhale, G.N., Khanzone S.D., Khanzone, S.S. and Saoji, A. (2005). Supplementation of 
vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome 
of schixophrenia. Psychopharmacology, 182, 494-498.  
 
Du Bois, T. M., Chao D. and Huang X-F. (2005). Membrane phospholipid composition, 
alterations in neurotransmitter systems and schizophrenia. Progress in Neuro-
Psychopharmacology & Biological Psychiatry, 29, 878-888. 
 
Egeland, J., Sundet, K., Rund, B.R., Asbjørnsen, A., Hugdahl, K., Landrø, N.I., Lund, A., 
Roness, A. and Stordal, K.I. (2003). Sensivity and specificity for memory dysfunction in 
schizophrenia: A comparison with major depression. Journal of clinical and experimental 
neuropsychology, 25, 79-93. 
 
Egeland, J.and Landrø, N.I. (2005). Hukommelsesforstyrrelsr ved schizofreni. (Memory 
deficits in schizophrenia). In Rund, B.R.(Ed.) Schizofreni (Schizophrenia). (pp.119-137), 
(2end ed.). Hertervig Forlag (Hertevig Publications). 
 
Emsley, R., Myburgh, C., Oosthuizen P. and van Rensburg, S.J. (2002). Randomized, 
placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in 
schizophrenia. American Journal of Psychiatry, 159, 1596-1598. 
  
Emsley, R., Niehaus, D.J., Koen, L., Oosthuizen, P., Turner, H.J., Carey, P., van Rensburg, 
S.J., Maritz, J.S. and Murck, H. (2006). The effects of eicosapentaenoic acid in tardive 
dyskinesia: a randomized, placebo-controlled trial. Schizophrenia Research, 84, 112-120. 
 
 43
Fendri, C., Mechri, A., Khiari, G., Othman, A., Kerkeni, A., and Gaha, L. (2006). Oxidative 
stress involvement in schizophrenia pathophysiology: a review. Encephale, 32, 244-252. 
 
Fenton, W.S., Dickerson, F., Bonerow, J., Hibbeln, J.R. and  Knable, M. (2001). A placebo-
controlled trial of omega-3 fatty acids (Ethyl Eichosapentaenoic Acid) supplementation for 
residual symptoms and cognitive impairment in schizophrenia. The American Journal of 
Psychiatry, 158, 2071-2074. 
 
Fenton, W.S., Hibbeln, J.R. and Knable, M., (2000). Essential Fatty Acids, Lipid Membrane 
Abnormalities and the Diagnosis and Treatment of Schizophrenia. Biological Psychiatry, 
47, 8-21. 
 
Fitzmaurice, G.M., Laird, N.M. and Ware, J.H., (2004). Applied Longitudinal Analysis. 
Wiley: New Jersey. 
 
Fontani, G., Corradeschi, F., Felici, A., Alfatti, F., Migliorini, S. and Lodi, L. (2005). 
Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation 
in healthy subjects. European Journal of Clinical Investigation, 35, 691-699. 
 
Francey, S.M., Jackson, H.J., Phillips, L.J., Wood, S.J., Yung, A.R. and McGorry, P.D. 
(2005). Sustained attention in young people at high risk of psychosis does not predict 
transition to psychosis. Schizophrenia Research, 79, 127-136.  
 
Gazzagnia, M.S., Ivry, R.B. and Mangun, G.R. (2002). Cognitive Neuroscience.The 
biology of the mind. (pp .245-300 and pp.500-536). W.W. Norton & Company, second 
edition.  
 
Gold, S., Arndt, S., Napoulos, P., O`Leary, D.S. and Andreasen, N.C. (1997). Longitudinal 
study of cognitive function in first-episode and recent-onset schizophrenia. The American 
Journal of Psychiatry, 156, 1342-1348. 
 
Glen, A.I.M., Glen, E.M.T., Horrobin, D.F., Vaddadi, K.S., Spellman, M., Morse-Fisher, 
N., Ellis, K. and Skinner, F.S. (1994). A red cell membrane abnormality in a subgroup of 
schizophrenic patients: evidence for two diseases. Schizophrenia research, 12, 53-61. 
 44
 
 
Green, M.R., Nuechterlein, K.H. and Gold, J.H. (2004). Approaching a consensus cognitive 
battery for clinical trails in schizophrenia: The NIMH-MATRIX conference to select 
cognitive domains and test criteria. Biological Psychiatry, 56, 301-307. 
 
Green, M. F. (2006). Cognitive impairment and functional outcome in schizophrenia and 
bipolar disorder. Journal of Clinical Psychiatry, 67, e12 
 
Grodstein, F., Chen, J. and Willett, W.C.(2003). High-dose antioxidant supplements and 
cognitive function in community-dwelling elderly women. The American journal of 
Clinical Nutrition, 77, 975-984.  
 
Halliday, G.M. (2001). A review of the neuropathology of schizophrenia. Clinical 
Experimental Pharmacology & Physiology, 28, 64-65.  
 
Harrison, P.J. (2004). The hippocampus in schizophrenia: a review of the neuropathological 
evidence and its pathophysiological implications. Psychopharmacology, 174, 151-162. 
 
Hong, K.S., Kim, J.G., Koh, H.J., Koo, M.S., Kim, J.H. and Lee, D. et al.(2002). Effects of 
risperidone on information processing and attention in first-episode schizophrenia. 
Schizophrenia Research, 53, 7-16. 
 
Hollis, C. (2005). Schizophrenia and allied disorders. In Rutter, M. and Taylor, E. (Eds.), 
Child and adolescent Psychiatry (pp. 612-635) (4th ed.). Malden: Blackwell Publishing. 
 
Helland, I.B., Smith, L., Saarem, K., Saugstad, O.D. and Drevon, C.A.(2003). Maternal 
supplementation with very-long-chain Omega-3 fatty acids during pregnancy and lactation 
augments childrens`IQ at four years of age. Pedriatrics, 111, 39-44. 
 
Horrobin, D.F. (1997). The membrane phospholipid hypothesis as a biochemical basis for 
the neurodevelopmental concept of schizophrenia. Schizophrenia research, 30, 193-208. 
 
 45
 
Hibbeln, J.R., Makino, K.K., Martin, C.E., Dickerson, J.B. and Fenton, W.S. (2003).  
Smoking, gender, and Dietary influences on Erythocyte essential fatty Acid Composition 
among Patients with Schizophrenia or Schizoaffective Disorder. Biological Psychiatry, 53, 
431-441. 
 
Horrobin, D.F. (1977). Schizophrenia as a prostaglandin deficiency disease. The Lancet, 30, 
936-937. 
Hyllestad, A. (1996). [Schizophrenia. Current biological theories on the etiology]. Ugeskrift 
for Laeger, 22,158, 4273-4277 
 
Javitt, D.C. and Laurelle M. (2006). Neurochemical theories. In Lieberman, J.A., Stroup, 
T.A. and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.85-116), (1st Ed.). The 
American Psychiatric Publishing. 
 
Jones, S.R. and Fernyhough, C. (2006). A New Look at the Neural Diathesis-Stress Model 
of Schizophrenia: The Primacy of Social-Evaluative and Uncontrollable Situations. 
Schizophrenia Bulletin, 14, 1-7.  
 
Jeding, I., Evans, P.J., Akanmu, D., Dexter, D., Spencer, J.D., Aruoma, O.I., Jenner, P. and 
Halliwell, B. (1995). Characterization of the potential antioxidant and pro-oxidant actions 
of some neuroleptic drugs. Biochemical Pharmacology, 31, 359-365. 
  
Joy, C.B., Mumby-Croft, R. and Joy, L.A. (2006). Polyunsaturated fatty acid 
supplementation for schizophrenia. Cochrane Database of Systemic Reviews, 19, 
3:CD001257. 
 
Kang, J.H., Cook, N., Manson, J., Buring, J.E. and Grodstein, F. (2006). A randomized trial 
of vitamin E supplementation and cognitive function in women. Archives of Internal 
Medicine, 166, 2462-2468. 
 
Keefe, R.S., Eesley, C.E. and Poe, M.P.(2005). Defining a cognitive function decrement in 
schizophrenia. Biological Psychiatry, 57, 688-691. 
 
 46
Keefe, R.S.E. and Eesley, C.E. (2006). Neurocognitive impairments. In Lieberman, J.A., 
Stroup, T.A. and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.245-261), (1st ed.). 
The American Psychiatric Publishing. 
 
Keri, S. and Janka, Z. (2004). Critical evaluation of cognitive dysfunctions as 
endophenotypes of schizophrenia. Acta Psychiatrica Scandinavica, 110, 83-91. 
 
Keshavan, M. S., Anderson, S. and Pettegrew, J. W. (1994). Is schizophrenia due to 
excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. 
Journal of Psychiatric Research, 28, 239-265.  
 
Keshavan, M.S., Gilbert, A.R., Diwadkar, V.A. (2006). Neurodevelopmental Theories. In  
Lieberman, J.A., Stroup, T.A. and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.69-
84), (1st ed.). The American Psychiatric Publishing. 
 
Khan, M.M., Evans, D.R., Gunna, V., Scheffer, R.E., Parikh, V.V., Mahadik, S.P. (2002). 
Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in 
schizophrenia at the never-medicated first-episode of psychosis and after years of treatment 
with antipsychotics. Schizophrenia Research, 58, 1-10. 
 
Kringlen, E. (2001). Psykiatri (Psychiatry). Schizofreniene (The group of schizophrenia). 
(pp. 268-296). Gyldendal Norsk Forlag AS. 
 
Lacritz, L.H. and Cullum, C.M. (1998). The Hopkins Verbal Learning Test and CVLT: A 
preliminary comparison. Archives of Clinical Neuropsychology, 13, 623-628. 
 
Laugharne, J.D., Mellor, J.E. and Peet, M. (1996). Fatty acid and schizophrenia. Lipids, 31, 
163-165. 
 
Lauritzen, L., Jorgensen, M.H., Hansen, H.S. and Michalsen, K.F. (2002). Fluctations in 
human milk long-chain PUFA-levels in relation to dietary fish intake. Lipids, 37, 237-244. 
 
Lewis, R. (2004). Should cognitive deficit be a diagnostic criterion for schizophrenia? 
Journal of Psychiatry Neuroscience, 29, 102-113. 
 47
 
Lezak, M.D., Howieson, D.B. and Loring, D.W. (2004). Orientation and attention. (pp.337-
368). Neuropsychological assessment. (4th edition.) New York: Oxford University. 
 
Liberman, R.P., Kopelowicz, A., Ventura, J. and Gutkind, D. (2002). International Review 
of Psychiatry, 14, 256-272. 
 
Lindenmayer, J.P. and Khan, A. (2006). Psychopathology. In Lieberman, J.A., Stroup, T.A. 
and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.187-221) (1st ed.). The American 
Psychiatric Publishing. 
 
Lingjærde, O. (2002). Nevrobiologiske funn ved schizofreni. (Neurobiological evidence in 
schizophrenia). Tidsskrift for Norsk Lægeforening, 122, 2123-2127. 
 
Liu, S.K., Hwu, H.G. and Chen, W.J. (1997). Clinical symptoms dimensions and deficits on 
the Continiuos Performance Test in schizophrenia. Schizophrenia Research, 25, 211-219. 
 
Liu, S.K., Hsieh, M.S., Hwang, T.J., Hwu, H.G., Liao, S.H., Lin, S.H. and Chen, W.J. 
(2006). Re-examening sustained attention deficits as vulnerability indicators for 
schizophrenia: Stability in the long term course. Journal of PsychiatricResearch, 40, 7, 613-
621. 
 
Mahadik, S.P., Pillai, A., Joshi, S. and Foster, A.(2006). Prevention of oxidative stress-
mediated neuropathology and improved clinical outcome by adjunctive use of a 
combination of antioxidants and omega-3 fatty acids in schizophrenia. International Review 
of Psychiatry 18, 119-131. 
 
Mahadik, S.P., Evans, D., Lal, H. (2001). Oxidative stress and role of antioxidants and 
omega-3 essential fatty acid supplementation in schizophrenia. (2001). Progressive 
Neuropsychopharmacol Biological Psychiatry, 25, 463-493. 
 
Mahadik, S.P. and  Mukherjee, S. (1996). Free radical pathology and antioxidant defence in 
schizophrenia: a review. Schizophrenia research, 19, 1-17. 
 
 48
Mahadik, S.P. and Gowda, S. (1996). Antioxidants in the treatment of schizophrenia. Drugs 
Today, 32, 1-13. 
 
Mahadik, S.P. and Evans, D. (1997). Essential fatty acids in the treatment of schizophrenia. 
Drugs Today, 33, 5-17. 
 
Mahadik, S.P., Mukherjee, S., Correnti, E.E., Kelkar, H.S., Wakade C.G., Costa, R.M. and 
Scheffer, R. (1994). Plasma membrane phospholipid and cholesterol distribution of skin 
fibroblasts from drug-naive patients at the onset of psychosis. Schizophrenia research, 13, 
239-247. 
 
Mahadik, S.P. and Yao, J.K. (2006). Phospholipids in Schizophrenia. In Lieberman, J.A., 
Stroup, T.A. and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.117-136), (1st ed.). 
The American Psychiatric Publishing. 
 
Malt, U. F., Retterstøl, N. and Dahl, A.A. (2003). Lærebok i psykiatri. (Textbook of 
psychiatry). Gyldendal Akademisk Forlag. (2nd edt.) Chap.7 and 9. 
 
Maxwell, C.J., Hicks, M.S., Hogan, D.B., Basran J.and Ebly, E.M. (2005). Supplemental 
use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. 
Dementia and Geriatric Cognitive Disorders, 20, 45-51. 
 
Merikangas, K.R. and Risch, N. (2003). Will the genomics revolution revolutionise 
psychiatry? American Journal of Psychiatry, 160, 625-635. 
 
Morris, M.C., Evans D.A., Tangney, C.C., Bienias J.L. and Wilson R.S. (2006). 
Associations of vegetable and fruit consumption with age-related cognitive change. 
Neurology, 24, 1370-1376. 
 
Morris, M.C., Evans, D.A., Dienias, J.L., Tangney C.C. and Wilson, R.S. (2002). Vitamin E 
and cognitive decline in older persons. Archives of Neurology, 59, 1125-1132. 
 
 
 49
Mueser, K.T. and Salyers, P.M. (2003). Scizophrenia. In Hersen, M. and Turner, S.M. 
(Eds.) 
 
Adult Psychopatology and Diagnosis. (4th ed.) John Wiley & Sons, Inc. 
 
Mueser, K.T. and McGurk, S.R. (2004). Schizophrenia. Lancet, 19, 2063-2072. 
 
Nuechterlein, K.H., Pashler, H.E., Subotnik, K.L. (2006). Translating basic attentional 
paradigms to schizophrenia research: reconsidering the nature of the deficits. Development 
and Psychopathology, 18, 831-851. 
 
Nadeem, Z., McIntosh, A., and Lawrie, S. (2004). Schizophrenia. Evidence –Based Mental 
Health, 7, 2-3. 
 
McNamera, R.K. and Carlson, S.E..(2006). Role of omega-3 fatty acids in brain 
development and function: potential implications for the pathogenesis and prevention of 
psychopathology. Prostaglandins, Leukotrienes and Essential fatty acids, 75, 329-349. 
 
Peet, P.J. (2001). A healthy body, a healthy mind: long-term impact of diet on mood and 
cognitive function. Proceedings of the Nutrition Society, 60, 135-143. 
 
Peet, M., Laugharne, J., Rangarajan, N., Horrobin, D. and Reynolds, G.(1995). Depleted red 
cell membrane essential fatty acids in drug-treated schizophrenic patients. Journal of 
Psychiatric Research, 29, 227-32. 
 
Peet, M., Laugharne J.D.E, Mellor J. and Ramchand, C.N. (1996). Essential fatty acid 
deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical 
effects of dietary supplementation. Prostaglandins, Leukotrienes and Essential Fatty Acids, 
55, 71-75. 
Peet, M.and Horrobin, D.F. (2002). (E-E Multicentre Study Group): A dose-ranging 
exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent 
schizophrenic symptoms. Journal of Psychiatry Research, 36, 7-18 
 50
Perkins, D.O., Lieberman, J.A. and Lewis, S. (2006). First episode. In Lieberman, J.A., 
Stroup, T.A. and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.353-365), (1st ed.). 
The American Psychiatric Publishing. 
Perkins, D.O., Miller-Andersen, L. and Lieberman, J.A. (2006). Natural history and 
predictors of clinical course. In Lieberman, J.A., Stroup, T.A. and Perkins, D.O. (Eds.). 
Textbook of Schizophrenia (pp.289-301), (1st ed.). The American Psychiatric Publishing. 
Posner, M. I.and Dehaene S. (1994). Attentional networks. Trends in Neuroscience, 17, 75-
79. 
 
 
Posner, M. I. and Petersen S. E. (1990). The attention system of the human brain. Annual 
Review of Neuroscience, 13, 25-42. 
 
Reddy, R. D., Keshavan, M.S., and Yao, J.K. (2004). Reduced red blood cell membrane 
essential polyunsaturated fatty acida in first episode schizophrenia at neuroleptic – naïve 
baseline. Schizophrenia Bulletin, 30, 901-911.  
 
Reddy, R.D. and Yao, J.K. (1996). Free radical pathology in schizophrenia: a review. 
Prostagladins, Leucorienest and Essential Fatty Acids, 55, 33-43. 
 
Ross, B.M., Hudson, C., Erlich, J., Warsh, J.J. and Kish, S.J. (1997). Increased 
phospholipid breakdown in schizophrenia. Archives of Geneneral Psychiatry, 54, 487-494. 
 
Skrede, S. and Holmsen, H. (2003). Har antipsykotika en rolle i membranhypotesen ved 
schizofreni? (Does antipsychotic medication have a role in the membrane hypothesis of 
schizophrenia?) Tidsskrift for Norsk lægeforening, 18, 2568-2570. 
 
Smith, A., Clark, R., Nutt, D., Haller, J., Hayward, S. and Perry, K. (1999). Anti-oxidant 
vitamins and mental performance of the elderly. Human Psychopharmacology-Clinical and 
Experimental, 14, 459-471.  
 
 51
Smith, A. P., Clark, R. E.., Nutt, D. J., Haller, J.G., Hayward, S. and Perry, K. (2000). 
Vitamin C, mood and cognitive function in the elderly. Nutritional Neuroscience, 2, 249-
256. 
 
Shriqui, C. L., Bradwejn, J., Annable, L. and Jones, B. D. (1992). Vitamin E in the 
treatment of tardive dyskinesia: a double-blind placebo-controlled study. American Journal 
of Psychiatry, 149, 391-393. 
 
Spreen, O. and Strauss, E. (1998). A Compendium of neuropsychological tests: 
Administration, norms and commentary (2nd Ed.). New York: Oxford University Press. 
 
Sullivan, P.F, Owen, M.J., O`Donovan, M.C. and Freedman, R. (2006). Genetics. In 
Lieberman, J.A., Stroup, T.A. and Perkins, D.O. (Eds.). Textbook of Schizophrenia (pp.39-
55), (1st Ed.). The American Psychiatric Publishing. 
 
Thaden, E., Rhinewine, J.P., Lencz, T., Kester, H., Cervellione, K.L., Henderson, I., 
Roofeh, D., Burdick, K.E., Napolitano, B., Cornblatt, B.A. and Kumra, S. (2006). Early-
onset schizophrenia is associated with impaired adolescent development of attentional 
capacity using the identical pairs continuous performance test.  Schizophrenia research, 81, 
157-166. 
 
Torgalsbøen, A-K. , (2005). Schizofreni og full restitusjon. (Schizophrenia and full 
restitution). In Rund, B.R.(Ed.) Schizofreni (Schizophrenia) (pp.87-103), (2nd ed.). 
Hertervig Forlag (Hertevig Publications). 
 
Tsuang, M.T. and Faraone, S.V. (2002). Diagnostic concepts and the prevention of 
schizophrenia. Canadian Journal of Psychiatry, 47, 515-517. 
 
Tu, X.M, Zhang J., Kowalski, J., Shults J., Feng C., Sun, W. and Tang, W. (2006). Power 
analyses for longitudinal study designs with missing data. Statistics in Medicine, 8, (Epub 
ahead of print). 
 
Yao, J.K., Reddy R.D. and van Kammen D.P. (2001). Oxidative damage and schizophrenia; 
an overview of its evidence and therapeutic implications. CNS Drugs, 15, 287-310. 
 52
 
Young, G. and Conquer J. (2005). Omega-3 fatty acids and neuropsychiatric disorders. 
Reproduction, Nutrition, Development, 45, 1-28. 
 
Yucel, M., Pantelis, C., Stuart, G.W., Wood, S.J., Maruff, P., Velakoulis, D., Pipingas, A., 
Crowe, S.F.. Tochon-Danguy, H.J. and Egan, G.F. (2002). Anterior cingulate activation 
during Stroop task performance: a PET to MRI coregistration study of individual patients 
with schizophrenia. American Journal of Psychiatry, 159, 251-254. 
 
Zielasek, J., Ehlis, A.-C., Herrmann, M.J. and Fallgatter, A.J. (2004). Reduced prefrontal 
response control in patients with schizophrenias: a subgroup analysis. Journal of neural 
Transmission, 112, 969-977.  
 
Ueland, T. (2005). Kognitiv trening ved schizofreni.(Cognitive training in schizophrenia). 
In Rund, B.R.(Ed.) Schizofreni (Schizophrenia) (pp.270-287), (2nd ed.). Hertervig Forlag 
(Hertevig Publications). 
 
Wang, Q., Chan, R., Sun, J., Yao, J., Deng, W., Sun, X., Liu, X., Sham, P.C., Ma, X., 
Meng, H., Murray, R.M., Collier, D.A. and Li, T. (2006). Reaction time of the Continiuos 
Performance Test is an endophenotypic marker for schizophrenia: A study of firs-episode 
neuroleptic-naïve schizophrenia, their non-psychotic first-degree relatives and healthy 
population controls. Schizophrenia Research, 89, 293-298. 
 
Werkman, S.H. and Carlson, S.E. (1996). A randomized trial of visual attention of preterm 
infants fed docosahexaenoic acid until nine months. Lipids, 31, 91-97. 
 
Wolf, G. (1997). Gamma-Tocopherol: an efficient protector of lipids against nitric oxide-
initiated peroxidative damage. Nutrition Reviews, 55, 376-378. 
 
 
 
 
 
 
 53
10.0 Appendix 
 
10.1 The neuronal membrane 
 
 Figure 1 
 
 
Source: Adapted from Mahadik and Yao, 2006. 
 
Figure 1 illustrates the membrane key structures and their function in cell-cell interaction, 
interaction with environmental factors and receptor-mediated signal transduction (Mahadik 
and Yao, 2006). The representation gives a picture of the phospholipid bilayer where 
receptors for e.g. neurotransmitters, growth factors, ions and nutrition are embedded. The 
phospholipid bilayer constitutes four major phospholipids that are asymmetrically localized. 
Some of the phospholipids are highly enriched in arachidonic acid (AA) and 
docosahexaenoic acid (DHA) which are released by receptor –mediated phospholipases 
(PLAs). AA and DHA and their metabolic products work as second messagers and 
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physiological mediators, including gene modulation and hence lead to adaptive and 
maladaptive cellular changes.  
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10.2 Signal detection theory 
 
RESPONSE CRITERION 
Response criterion refers to an operators set of rules that they develop when involved in a 
signal detection task.  As we will see later this can be manipulated either by motivation or 
expectancy.   
Before discussing the types of criterion and their implications, lets take a look at the 
relationship of probability, possible responses, and stimulus in the environment.   
 
• The curve on the left represents the probability that the detection of the signal is due 
to noise alone.  
• The curve on the right represents the probability that the detection of the signal is to 
the presence of the signal.  
• The point in the center of the intersection represents the point where the detection of 
the signal is equally probable both to the presence of noise or signal plus noise.  
• The area of overlap is where an error occurs, either miss or false alarm.    
If the sensation level is above a particular level called the response bias and symbolized 
with the Greek letter (ß) or beta, the observer says "yes"; if it is below the response bias 
level the observer says "no." 
• Signal detection theory assumes that an optimal strategy is used on every trial of an 
experiment.  
There are three types of response criterions in which an operator may adopt each with their 
own implications: 
• Liberal--More likely to say signal present most of the time; produces high # hits 
and false alarms.  
• Neutral--Equal probability of hits and false alarms  
• Conservative--more likely to say no signal present most of the time; produces low # 
hits and false alarms.  
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In terms of graphic representation below Xc represents the decision criterion.  Beta (ß) 
represents the response bias (ß) which is a ratio measure of neural activity. Both beta and 
Xc define the response criterion  
Neutral  
 
As you can see, there is an equal probability of getting either a miss or a false alarm.  
Beta=1.0  
Liberal  
 
Here the operator says "yes, signal present" all the time leading to high rate of false alarms 
and a high rate of hits.  Beta  < 1.0  
Conservative  
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Here the operator says "no, there is no signal present" most leading to a low number of hits 
& high number of misses yet few false alarms.  Beta > 1.0        
 
 
Sensitivity 
Sensitivity refers to the keenness or resolution of the detection mechanisms in an operator.  
Theoretically, sensitivity refers to the separation of the means of the two distributions for 
noise and signal + noise along the X axis (See Below).  This is represented by d'.  On the 
next page it is discussed later how to calculate d' from a single outcome matrix. 
 
The greater the distance between these two points, the greater the sensitivity, and the higher 
the value of d'. 
 
The greater the sensitivity of the operator, the less probability there are for errors.  
Remember that the area of the overlap represents the chances for probability of an error.  
Therefore the less overlap there is between the two, the less chance for error.   
Like biases, sensitivity also has an optimal level.  The setting of this level is quite complex 
and can really only be done in a carefully controlled environment.  It requires defining 
precisely the statistical properties of the physical energy in the signal and no signal trials.  
Operators sensitivity often drifts from optimal sensitivity because the characteristics of the 
signal are often forgotten.  
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Calculating Sensitivity 
There are two methods of calculating sensitivity.  One is based on theoretical assumptions 
and the other is based on empirical data. 
d'-Theoretical Approach 
Data required for each point on an ROC curve requires hundreds of trials (to get accurate 
probabilities for Hits and False Alarms). With a few theoretical assumptions, d' can be 
calculated from a single outcome matrix.  
This method assumes that:  
• Noise is normally distributed. Presenting a signal on top of that noise, will therefore 
shift the amount of sensory activity to the right (higher), by an amount equal to that 
sensory systems sensitivity to that signal.   
o The difference between the mean amount of sensory activity generated by 
the noise alone trials and the signal+noise trials will equal sensitivity (d') 
measured in z-score (standard deviation) units.  
• Participants adopt a criterion for dealing with those values of sensory activity that 
could result from either noise alone or signal plus noise (the area where the noise 
and signal+noise distributions overlap).   
o If the amount of sensory activity exceeds that amount, the participant will 
say the detected the signal, any amount less than that and they will say they 
did not detect the signal.  
With these assumptions, the four cells of an outcome matrix can be represented as areas 
under the two normal distributions .  
d' = ZFA - ZHit  
Tables for the z-score distribution or percent area under the normal curve typically present 
the z-score distances between the mean and the criterion value beta.   
• If you are using such a table, ZFA can be found by looking up the z-score associated 
with (50 - False Alarm %).   
o If this number is positive, then the z-score to be put into the above formula 
will also be positive,   
o If it is negative, the z-score value for the formula will also be negative.   
o It is essential that the proper signs be used. A good way of checking would 
be to draw the distributions and the criterion and see the relationship 
between d' and the two z-scores.   
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• Similarly, to find ZHit, look up (50 - Hit %), again, the resulting sign will be the 
same as is used for the z-score in the formula.  
Proportion of Responses 
Signal  
Yes No 
Present  .60 .40 
Absent  .20 .80 
  
d' = ZFA - ZHit 
d' = Z (50-20) - Z (50-60)   
Looking up the z-score associated with 50-20= 30% of the area under the normal curve, it is 
.842; for 50-60= -10% it is .253. Since 50 - 60 is a negative, -.253 is put into the formula to 
get:  
d' =.842-(-.253) = .842+.253= 1.095 
 
 
Empirical Approach 
A distinction should be made between actual empirical data collected in a signal detection 
experiment and the theoretical method discussed above. 
• Distributions of noise and signal plus noise are not precisely normal and of equal 
variance, especially if there is variability in the signal.  
• Data collected would consist of a set of discrete points rather than a continuous 
smooth curve.  
• Empirical results in which data are collected from a subject as the criterion is varied 
provide points that do not fall precisely along a line of constant bowedness as shown 
in the ROC curve.  
• Although it is desirable to generate two or more points on the ROC curve, this may 
impossible to do.    
o The experimenter often has neither the luxury nor feasibility of manipulating 
beta or using rating scales and must use the data available from a single 
response matrix.  
Under these circumstances there is an alternative measure of sensitivity.   
This measure is known as P(A)--the area under the ROC curve. 
• This represents the area to the right and below the line segments connecting the 
lower left and upper right corners of the ROC space to the measured data point (See 
Below).  
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This measure does not depend on any assumptions concerning the shape or form of 
the underlying signal and noise distributions.   
P(A) may be calculated by the following formula: 
 
   Adapted from: http://www.csulb.edu/org/hfes/responsecriterion.htm 
 
. 
 
 
 
 
 
